Biomarkers — What Does Your Blood Test Measure?

Histamine is a biogenic amine and signalling molecule that plays a central role in immune responses, allergic reactions, gastric acid secretion, and neurotransmission. It is produced by mast cells and basophils (immune cells), enterochromaffin-like cells in the stomach, and neurons in the brain. In the context of allergy, histamine is the primary mediator released when IgE-bound mast cells are activated by an allergen.

Histamine intolerance is a condition in which the body accumulates excess histamine from dietary sources or internal production, combined with reduced capacity to break it down (due to deficiency of the enzyme diamine oxidase, DAO). This can cause symptoms including headaches, flushing, urticaria, nasal congestion, itching, palpitations, and gastrointestinal distress, mimicking allergic reactions but without IgE involvement.

Coenzyme Q10 (CoQ10), also known as ubiquinol (reduced form) or ubiquinone (oxidised form), is a fat-soluble compound found in virtually every cell in the body. It is essential for mitochondrial energy production, serving as a critical electron carrier in the inner mitochondrial membrane where it helps generate ATP, the cell's primary energy currency. CoQ10 is also a potent antioxidant, protecting cell membranes and mitochondrial DNA from oxidative damage.

The body produces CoQ10 naturally, but production declines with age from around the fourth decade. CoQ10 is also depleted by statin medications, which block the same biochemical pathway (the mevalonate pathway) used to synthesise both cholesterol and CoQ10. Dietary sources include organ meats, oily fish, and nuts, but dietary intake alone provides only a small proportion of the body's needs relative to endogenous synthesis.

The Omega-3 Index measures the amount of two key omega-3 fatty acids — EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) — as a percentage of the total fatty acids in red blood cell membranes. Because red blood cells live for approximately 90–120 days, the Omega-3 Index reflects average omega-3 intake and status over the preceding 3 months, making it a stable and reliable long-term biomarker.

An Omega-3 Index above 8% is considered optimal and is associated with the lowest cardiovascular risk. An index below 4% is considered a risk factor comparable in magnitude to smoking. Most Australians fall in the 4–8% range. The index is raised by regular consumption of oily fish (salmon, sardines, mackerel) and omega-3 supplements, and can be used to guide and monitor supplementation.

RBC glutathione peroxidase (GPx) measures the activity of the antioxidant enzyme glutathione peroxidase inside red blood cells. GPx is a selenium-dependent enzyme that neutralises hydrogen peroxide and lipid peroxides, protecting cells from oxidative damage. Measuring its activity in red cells provides a sensitive marker of both selenium nutritional status and overall antioxidant defence capacity.

Because GPx activity is measured over the lifespan of red cells (approximately 120 days), it reflects selenium status and antioxidant function over the preceding 3-4 months, making it more informative than plasma selenium for assessing chronic selenium adequacy. It is particularly useful in evaluating functional selenium deficiency even when serum selenium appears borderline.

Anti-nuclear antibodies (ANA) are autoantibodies produced by the immune system that target proteins within the nucleus of cells. In healthy individuals, the immune system does not attack the body's own tissues. In autoimmune conditions, this self-tolerance breaks down and the immune system generates antibodies against nuclear components including DNA, histones, and nuclear ribonucleoproteins.

ANA testing is performed by indirect immunofluorescence, where the patient's serum is applied to cells on a slide and the pattern and titre of fluorescence are assessed. ANA is a broad screening test — a positive result does not diagnose a specific disease but indicates that autoimmune activity is present. Further specific antibody tests (such as anti-dsDNA, anti-Sm, anti-Ro, anti-La, anti-Scl-70) are then used to identify the precise autoimmune condition.

The ANA pattern describes the distribution of fluorescence seen when a patient's serum is tested for anti-nuclear antibodies (ANA) by indirect immunofluorescence on HEp-2 cells. The pattern reflects which specific nuclear or cytoplasmic components are being targeted by the autoantibodies, and different patterns are associated with different autoimmune conditions.

The four main ANA patterns are: homogeneous (diffuse staining of the nucleus, associated with anti-dsDNA and anti-histone antibodies, seen in lupus); speckled (irregular nuclear staining, associated with anti-Sm, anti-Ro, anti-La, and anti-RNP, seen in lupus, Sjögren's, and MCTD); nucleolar (staining of the nucleolus, associated with scleroderma-related antibodies); and centromere (discrete nuclear spots, associated with limited scleroderma and CREST syndrome).

The ANA titre measures the concentration of anti-nuclear antibodies in the blood, expressed as the highest dilution of serum at which ANA fluorescence is still detectable. It is reported as a ratio — such as 1:40, 1:80, 1:160, 1:320, or 1:640 — where higher numbers indicate greater antibody concentration and a stronger autoimmune response.

The ANA titre provides important context for interpreting a positive ANA result. Low titres (1:40 to 1:80) are common in healthy individuals and rarely indicate significant autoimmune disease. Higher titres (1:160 and above) are more clinically meaningful and, when combined with compatible symptoms and patterns, increase the likelihood of a systemic autoimmune connective tissue disease such as lupus or Sjögren's syndrome.

Rheumatoid factor (RF) is an autoantibody, most commonly IgM class, that binds to the Fc region of IgG immunoglobulins. It is produced by plasma cells in the synovium (joint lining) and lymph nodes in people with autoimmune conditions, particularly rheumatoid arthritis (RA). RF is one of the serological markers used in the diagnosis of RA alongside anti-CCP antibodies.

RF is not specific to rheumatoid arthritis and can be positive in other conditions including Sjogren's syndrome, other autoimmune diseases, chronic infections, viral hepatitis, and in a small percentage of healthy older adults. Anti-CCP is more specific for RA than RF alone. RF positivity combined with anti-CCP positivity strongly supports RA diagnosis and predicts more erosive disease.

Biological age is a measure of how well your body is functioning relative to its chronological age — the number of years you have been alive. While everyone ages chronologically at the same rate, the rate at which the body's cells, tissues, and organ systems age is highly variable and influenced by genetics, lifestyle, environment, and medical history. Biological age captures this variation.

Biological age can be estimated from multiple types of data: blood biomarkers (such as clinical chemistry panels, inflammation markers, metabolic markers), epigenetic clocks (measuring DNA methylation patterns that change predictably with age), and physiological measures (grip strength, walking speed, lung function). A biological age younger than chronological age suggests the body is ageing more slowly than average; an older biological age indicates accelerated ageing and is associated with higher risk of age-related disease and earlier mortality.

DNAm PhenoAge is an epigenetic clock that estimates biological age from DNA methylation patterns measured in blood. DNA methylation involves the addition of methyl groups to cytosine bases at specific sites across the genome, and these patterns change in a predictable, age-related way. DNAm PhenoAge was developed by Dr Morgan Levine and colleagues at Yale University using methylation data from thousands of individuals, trained to predict a composite measure of biological age derived from clinical biomarkers.

Unlike biological age estimates based on blood chemistry panels, DNAm PhenoAge reads the epigenetic state of the genome directly, providing a measure that is closer to the cellular ageing process itself. A DNAm PhenoAge lower than chronological age suggests the cellular environment is ageing more slowly than average; a higher epigenetic age indicates cellular ageing is accelerated and is predictive of increased all-cause mortality, disease risk, and reduced healthspan.

The ABO blood group system classifies blood into four main types — A, B, AB, and O — based on the presence or absence of specific antigens (A and B antigens) on the surface of red blood cells, and corresponding antibodies in the plasma. Blood type A has A antigens and anti-B antibodies; type B has B antigens and anti-A antibodies; type AB has both antigens and no antibodies; type O has neither antigen but both antibodies.

ABO blood typing is essential before any blood transfusion or organ transplant to prevent potentially fatal immune reactions. Research has also linked blood type to varying risks of certain conditions including cardiovascular disease, certain cancers, and susceptibility to specific infections — though blood type alone is not a strong clinical risk factor for most conditions.

The activated partial thromboplastin time (APTT) measures how long it takes for a clot to form in a plasma sample when the intrinsic coagulation pathway is activated. It assesses the function of clotting factors involved in the intrinsic and common pathways — specifically factors XII, XI, IX, VIII, X, V, II (prothrombin), and fibrinogen.

APTT is used to investigate unexplained bleeding (bruising, prolonged bleeding from cuts, haemarthrosis), diagnose clotting factor deficiencies including haemophilia A (factor VIII) and haemophilia B (factor IX), and monitor heparin anticoagulation therapy. A prolonged APTT indicates impaired clot formation; a shortened APTT may suggest a hypercoagulable state.

D-dimer is a small protein fragment produced when a blood clot dissolves (fibrinolysis). When a clot forms anywhere in the body, the clotting protein fibrin is deposited; as the clot breaks down, D-dimer is released into the bloodstream. Elevated D-dimer indicates that significant clot formation and breakdown have occurred recently.

D-dimer is most commonly used to rule out deep vein thrombosis (DVT) and pulmonary embolism (PE). A normal D-dimer in someone with low or intermediate clinical probability of DVT or PE effectively excludes the diagnosis. However, D-dimer is not specific — it can be elevated in many other conditions including pregnancy, infection, inflammation, cancer, trauma, and recent surgery — so a positive result requires further imaging to confirm clot.

ESR (erythrocyte sedimentation rate) measures how quickly red blood cells settle to the bottom of a vertical tube over one hour. When inflammation is present, proteins called acute phase reactants (particularly fibrinogen) cause red blood cells to clump together (form rouleaux), making them heavier and causing them to fall more quickly.

ESR is a non-specific marker of inflammation — a raised ESR indicates that something is causing inflammation somewhere in the body, but cannot identify the cause. It is elevated in autoimmune conditions (including rheumatoid arthritis, lupus, and polymyalgia rheumatica), infections, malignancy, and anaemia. ESR is often measured alongside CRP — the two tests are complementary, as ESR responds more slowly and can remain elevated longer after the acute inflammatory stimulus has resolved.

Fibrinogen is a soluble plasma protein produced by the liver that plays a central role in blood clotting. When vascular injury occurs, thrombin converts fibrinogen into fibrin, which forms the structural scaffold of a blood clot. Fibrinogen is also an acute phase reactant, rising significantly with inflammation, infection, and tissue injury.

Elevated fibrinogen is associated with increased cardiovascular risk, as it promotes platelet aggregation, increases blood viscosity, and is a key component of clot formation. High fibrinogen is an independent cardiovascular risk factor and is particularly relevant in people with metabolic syndrome, type 2 diabetes, or a strong family history of cardiovascular disease. Low fibrinogen, conversely, indicates impaired clotting capacity and increased bleeding risk.

Haematocrit (HCT) is the percentage of total blood volume occupied by red blood cells. It is a fundamental component of the full blood count and directly reflects the oxygen-carrying capacity of the blood. Haematocrit is closely related to haemoglobin concentration and red blood cell count.

Low haematocrit indicates anaemia — the red blood cells are diluted either because too few are being produced, they are being destroyed too rapidly, or blood has been lost. High haematocrit can indicate polycythaemia (excess red blood cell production), dehydration, or chronic hypoxia (as seen at high altitude or in chronic lung disease), where the body produces more red blood cells to compensate for low oxygen.

Haemoglobin is the iron-containing protein in red blood cells responsible for binding oxygen in the lungs and delivering it to tissues throughout the body. It also carries carbon dioxide from tissues back to the lungs for exhalation. Haemoglobin is the most direct measure of the blood's oxygen-carrying capacity.

Low haemoglobin defines anaemia — a condition that causes fatigue, breathlessness, pallor, poor concentration, and reduced exercise tolerance. The most common causes include iron deficiency, vitamin B12 deficiency, folate deficiency, chronic disease, and blood loss. The pattern of red blood cell indices (MCV, MCH, MCHC) alongside haemoglobin helps identify the type of anaemia and guide further investigation.

The International Normalised Ratio (INR) is a standardised measure of how long it takes for blood to clot, calculated from the prothrombin time (PT). Standardisation across different laboratories is achieved by adjusting for the sensitivity of the thromboplastin reagent used. INR is most commonly used to monitor warfarin (Coumadin) therapy — a widely used anticoagulant drug.

A normal INR is approximately 1.0. For most therapeutic indications, warfarin is dosed to achieve an INR of 2.0–3.0 (or 2.5–3.5 for mechanical heart valves). An INR below the target range means the blood is clotting too quickly — increasing the risk of dangerous blood clots. An INR above the range means the blood is clotting too slowly — increasing the risk of serious bleeding.

LDH-2 is the second isoenzyme of lactate dehydrogenase and is found predominantly in cardiac muscle and red blood cells. In a normal blood sample, LDH-2 is the most abundant isoenzyme, exceeding LDH-1. An elevated LDH-1 relative to LDH-2 (LDH-1 greater than LDH-2) — known as a 'flipped' LDH pattern — is a classic indicator of myocardial infarction or haemolysis.

While cardiac troponin has largely superseded LDH isoenzymes in the acute setting, LDH-2 testing remains useful when assessing haemolytic conditions — where increased red blood cell destruction releases LDH-2 into the bloodstream — and in haematological malignancies where red blood cell turnover is elevated.

MCH (mean corpuscular haemoglobin) measures the average amount of haemoglobin contained within a single red blood cell. It is a derived index calculated from the haemoglobin concentration and red blood cell count. MCH provides information about whether red blood cells are adequately filled with haemoglobin.

Low MCH (hypochromic cells — pale red blood cells with less haemoglobin) is most commonly caused by iron deficiency anaemia or thalassaemia trait. High MCH (hyperchromic cells) is associated with vitamin B12 or folate deficiency, where red blood cells are larger than normal (macrocytic). MCH is interpreted alongside MCV and MCHC to characterise the type of anaemia present.

MCHC (mean corpuscular haemoglobin concentration) measures the average concentration of haemoglobin within red blood cells — how densely packed the haemoglobin is per unit volume of cell. It is the most physiologically direct measure of red cell haemoglobin content.

Low MCHC indicates hypochromic anaemia where red cells are dilute in haemoglobin — most commonly from iron deficiency. Elevated MCHC is seen in hereditary spherocytosis (where red blood cells are abnormally spherical and dense) and can also be a laboratory artifact from haemolysis or hyperglycaemia. MCHC provides a useful check on other red cell indices and helps identify hereditary red cell disorders.

MCV (mean corpuscular volume) measures the average size of red blood cells in femtolitres (fL). It is one of the most clinically useful red blood cell indices for classifying anaemia and guiding further investigation.

Low MCV (microcytic anaemia — small red cells) is most commonly caused by iron deficiency or thalassaemia. Normal MCV (normocytic anaemia) is associated with anaemia of chronic disease, haemolytic anaemia, or early nutritional deficiency. High MCV (macrocytic anaemia — large red cells) is typically caused by vitamin B12 or folate deficiency, but can also result from alcohol excess, hypothyroidism, liver disease, or certain medications including methotrexate and hydroxyurea.

Monocytes are the largest type of white blood cell and serve as a critical bridge between the innate and adaptive immune systems. In circulation, they act as scavengers — patrolling for pathogens and damaged cells. When they migrate into tissues, they differentiate into macrophages and dendritic cells, where they process and present antigens to lymphocytes.

Elevated monocytes (monocytosis) are seen in chronic infections (tuberculosis, endocarditis), inflammatory bowel disease, autoimmune conditions, and certain blood cancers including chronic monocytic leukaemia. Low monocytes (monocytopenia) can occur with certain medications or bone marrow suppression. Monocyte count is reported as part of the white blood cell differential on a full blood count.

MPV (mean platelet volume) measures the average size of platelets in the blood. Like red blood cell size (MCV), platelet size provides useful clinical information about platelet production and function. Larger platelets are metabolically more active and contain more granules — substances released during clotting.

High MPV with normal or low platelet count suggests increased platelet destruction (as in immune thrombocytopenia) or increased platelet production from the bone marrow — larger platelets are released when production is ramped up. High MPV is also an independent cardiovascular risk marker, as larger platelets are more reactive and prothrombotic. Low MPV may indicate bone marrow suppression or nutritional deficiency reducing platelet production.

Neutrophils are the most abundant type of white blood cell, accounting for 50–70% of circulating white cells. They are the body's primary first-line responders to bacterial infection and acute inflammation — rapidly migrating to sites of infection, where they engulf and destroy pathogens through phagocytosis and by releasing antimicrobial enzymes and reactive oxygen species.

Elevated neutrophils (neutrophilia) typically indicate bacterial infection, inflammation, physiological stress (including exercise, pregnancy, surgery), or corticosteroid use. Low neutrophils (neutropenia) increase the risk of serious bacterial infection and can result from chemotherapy, bone marrow suppression, viral infections (including COVID-19 in some cases), autoimmune disorders, or medications.

The platelet count measures the number of platelets (thrombocytes) in a litre of blood. Platelets are small anucleate cell fragments derived from megakaryocytes in the bone marrow, essential for primary haemostasis through their ability to aggregate at sites of vascular injury and form the initial platelet plug.

Low platelet count (thrombocytopenia) increases bleeding risk; high platelet count (thrombocytosis) may increase clotting risk in some conditions. Platelet count is interpreted alongside platelet morphology (blood film), MPV, and clinical context. It is reported automatically as part of every full blood count.

Prothrombin time (PT) measures how quickly the extrinsic coagulation pathway — activated by tissue factor released from damaged blood vessel walls — leads to clot formation. It assesses clotting factors VII, X, V, prothrombin (factor II), and fibrinogen. Results are often reported as an INR for standardisation.

PT/INR is prolonged in liver disease (which impairs clotting factor synthesis), vitamin K deficiency, warfarin use, and clotting factor deficiencies. It is a key component of liver function assessment — a prolonged PT indicates severe hepatic dysfunction. PT is also used to assess clotting status before surgical procedures and to monitor warfarin therapy.

The red blood cell count (RBC) measures the total number of red blood cells in a litre of blood. Red blood cells (erythrocytes) are the most abundant cells in the blood and are responsible for transporting oxygen from the lungs to every tissue in the body, and carrying carbon dioxide back to the lungs for exhalation.

A low RBC count alongside low haemoglobin and haematocrit confirms anaemia. The pattern of RBC count with other indices (MCV, MCH, MCHC) helps classify the type of anaemia. A high RBC count (polycythaemia) can be primary (polycythaemia vera) or secondary to chronic hypoxia, dehydration, or exogenous erythropoietin administration. RBC is always interpreted as part of the complete blood count.

RDW measures variation in red blood cell size. High RDW indicates anisocytosis — red cells of significantly different sizes — occurring with mixed nutritional deficiencies or during early treatment response. RDW is most useful alongside MCV to classify anaemia and distinguish iron deficiency from thalassaemia trait.

The Rh (Rhesus) blood group system is the second most important blood group system after ABO. It classifies people as either Rh-positive (D antigen present on red blood cells) or Rh-negative (D antigen absent). Approximately 85% of Australians are Rh-positive; 15% are Rh-negative.

Rh compatibility is essential in blood transfusion — giving Rh-positive blood to an Rh-negative recipient can trigger antibody formation. The most important clinical context is pregnancy: if an Rh-negative mother carries an Rh-positive baby, her immune system may produce anti-D antibodies that can cross the placenta in subsequent pregnancies and cause haemolytic disease of the fetus and newborn (HDFN). Anti-D immunoglobulin (Rh immunoglobulin) is given prophylactically to prevent this.

Thrombin clotting time (TCT) measures the time for a fibrin clot to form after thrombin is added directly to a plasma sample, bypassing the earlier steps of the coagulation cascade. It specifically measures the final step of coagulation — thrombin's conversion of fibrinogen to fibrin.

TCT is prolonged when fibrinogen is low (hypofibrinogenaemia), abnormal (dysfibrinogenaemia), when thrombin inhibitors such as heparin or dabigatran are present in the sample, or when fibrin degradation products (from conditions like DIC) inhibit fibrin polymerisation. TCT is most commonly used to detect heparin contamination in blood samples and to investigate abnormal bleeding alongside PT and APTT.

Total iron binding capacity (TIBC) measures the maximum amount of iron that transferrin in the blood can carry. It is an indirect measure of transferrin concentration and reflects how much additional iron the blood could carry if transferrin were fully saturated with iron.

In iron deficiency, TIBC is elevated — the liver produces more transferrin, increasing the blood's capacity to bind any available iron. In iron overload or anaemia of chronic disease, TIBC is low or normal. TIBC is used alongside serum iron and transferrin saturation as part of a complete iron panel. Transferrin saturation (iron ÷ TIBC × 100) is the most useful derived value — low saturation indicates deficiency; high saturation indicates overload.

Transferrin is a plasma glycoprotein produced by the liver that serves as the primary transport protein for iron in the blood. Each transferrin molecule can bind up to two iron atoms and delivers iron to cells expressing transferrin receptors — particularly developing red blood cells in the bone marrow, which require iron for haemoglobin synthesis.

Transferrin levels rise when iron stores are low — the body produces more transferrin to maximise iron capture from the blood. This makes transferrin useful in distinguishing iron deficiency anaemia (high transferrin) from anaemia of chronic disease (low or normal transferrin). Transferrin is also used to calculate transferrin saturation and TIBC, which together give a complete picture of iron status.

Transferrin saturation (TSAT) expresses the percentage of transferrin binding sites that are currently occupied by iron. It is calculated from serum iron divided by TIBC, multiplied by 100. Normal TSAT is typically 20–50%.

Low TSAT (below 20%) indicates iron deficiency — little iron is available to bind to transferrin. High TSAT (above 50%) indicates iron overload — transferrin is saturated and non-transferrin-bound iron may accumulate in organs, causing the tissue damage seen in haemochromatosis. TSAT is an essential component of a complete iron panel, providing the most direct measure of iron availability for red blood cell production.

Parathyroid hormone (PTH) is produced by the four parathyroid glands located behind the thyroid gland. Its primary role is to regulate calcium and phosphate balance by stimulating bone resorption to release calcium, increasing renal calcium reabsorption, reducing phosphate reabsorption by the kidney, and stimulating activation of vitamin D to enhance intestinal calcium absorption.

PTH is measured when abnormal calcium levels are found on blood testing, when bone density loss needs investigation, or when symptoms of hypercalcaemia or hypocalcaemia are present. Together with calcium and vitamin D levels, PTH provides the key information for diagnosing the cause of calcium disorders including primary hyperparathyroidism, vitamin D deficiency, and hypoparathyroidism.

Bone ALP (bone-specific alkaline phosphatase, BSAP) is an enzyme produced by osteoblasts — the cells responsible for building new bone. It is released into the bloodstream during the process of bone formation and mineralisation. Because it is derived specifically from osteoblasts rather than other tissues, it provides a direct and specific measure of how actively new bone is being laid down, independent of liver or intestinal ALP.

Bone ALP is one of the key bone formation markers used to assess bone turnover — the continuous process of bone resorption and replacement that maintains skeletal integrity. Elevated bone ALP indicates accelerated bone formation, which occurs in conditions of high bone turnover such as Paget's disease of bone, hyperparathyroidism, bone metastases, and osteomalacia. In osteoporosis management, bone ALP helps track the effectiveness of bone-building medications such as teriparatide.

CA-125 (cancer antigen 125) is a protein found on the surface of many ovarian cancer cells and released into the bloodstream. It is the most widely used tumour marker for ovarian cancer, although it is not specific to ovarian cancer and can be elevated in many other conditions including endometriosis, fibroids, pelvic inflammatory disease, and various benign gynaecological conditions.

CA-125 is primarily used to monitor the response to treatment in women with confirmed ovarian cancer, and to detect recurrence after treatment. It is less useful as a standalone screening tool in the general population due to its low specificity — many women with elevated CA-125 do not have ovarian cancer, and approximately 20% of ovarian cancers (particularly early-stage mucinous types) do not produce CA-125. It is most clinically meaningful when used in combination with pelvic ultrasound and clinical assessment.

CA-215 is a tumour-associated antigen used as a biomarker in certain cancers. It belongs to the family of mucin-like antigens and is elevated in several malignancies including ovarian, cervical, endometrial, and other gynaecological cancers, as well as gastrointestinal cancers. It is typically measured as a complement to other tumour markers rather than as a standalone diagnostic test.

Like most tumour markers, CA-215 has limited utility as a primary screening tool due to overlap with benign conditions. Its greatest clinical value is in monitoring treatment response and detecting disease recurrence in patients with known cancers that produce this antigen. Serial measurements over time provide more clinically meaningful information than any single result.

GCT-ALP (germ cell tumour alkaline phosphatase), also known as placental-like ALP or Regan isoenzyme, is a specific isoenzyme of alkaline phosphatase that is normally expressed by placental tissue during pregnancy and by certain germ cell tumours. In non-pregnant individuals, its presence in the blood is strongly associated with malignancy.

GCT-ALP is elevated in a range of germ cell tumours including some testicular and ovarian germ cell cancers, and is also found in other malignancies including lung and gynaecological cancers. As part of the ALP isoenzyme profile, GCT-ALP helps identify the tumour source of an elevated total ALP result and provides diagnostic information in the investigation and monitoring of germ cell malignancies.

Placental alkaline phosphatase (PALP) is an ALP isoenzyme produced by placental syncytiotrophoblast cells during pregnancy. It is the dominant ALP isoenzyme in the third trimester and is physiologically elevated throughout pregnancy. In non-pregnant individuals, any detectable PALP is potentially pathological.

PALP is also known as the Regan isoenzyme when found outside of pregnancy, where it is a recognised paraneoplastic marker associated with several cancers including lung, ovarian, and gastrointestinal malignancies. Detection of PALP in a non-pregnant individual warrants investigation for underlying malignancy.

The Regan isoenzyme is a placental-type ALP found in non-pregnant individuals, produced ectopically by tumour cells. Its presence outside of pregnancy warrants investigation for malignancy, particularly lung, ovarian, and gastrointestinal cancers.

Apolipoprotein A1 (ApoA1) is the primary structural protein of HDL particles. Each HDL particle contains ApoA1, which is essential for reverse cholesterol transport — collecting cholesterol from arterial walls and returning it to the liver for excretion.

ApoA1 directly represents the number and functional capacity of HDL particles, making it a more accurate measure of cardioprotective capacity than HDL cholesterol concentration alone. Counting actual HDL particles makes ApoA1 a stronger cardiovascular risk predictor than HDL-C in many patient groups, particularly those with metabolic syndrome.

Apolipoprotein B (ApoB) is the primary structural protein of all atherogenic lipoprotein particles — LDL, VLDL, IDL, and Lp(a) each contain exactly one ApoB molecule. This makes ApoB measurement equivalent to counting the total number of atherogenic particles in the blood, regardless of how much cholesterol each particle carries.

ApoB is increasingly recognised as a superior marker of cardiovascular risk compared to LDL cholesterol. Because each ApoB-containing particle can cause arterial damage regardless of size, particle count (ApoB) is more predictive than the cholesterol mass (LDL-C). This is why some individuals with 'normal' LDL cholesterol still develop heart attacks — they may have a high number of small, cholesterol-depleted ApoB particles that standard tests undercount.

The ApoB/ApoA1 ratio compares apolipoprotein B — the protein found on every atherogenic lipoprotein particle (LDL, VLDL, IDL, Lp(a)) — with apolipoprotein A1, the main structural protein of protective HDL particles. It captures both the atherogenic burden and the protective capacity in a single ratio.

Research has shown the ApoB/ApoA1 ratio is one of the strongest predictors of cardiovascular risk available — superior to total cholesterol, LDL alone, or the standard cholesterol ratio in multiple large studies. A higher ratio means more atherogenic particles relative to protective ones. It is particularly useful in people with metabolic syndrome where standard lipid panels may appear deceptively normal.

Cholesterol lipid subfractions provide a detailed analysis of the lipoprotein particles carrying cholesterol through the blood. Rather than reporting a single LDL or HDL number, subfraction testing separates cholesterol into its distinct particle types — from large buoyant LDL-1 through progressively smaller and more atherogenic particles down to small dense LDL subfractions, alongside HDL subclasses and IDL.

This level of detail allows clinicians and individuals to understand not just how much cholesterol is present, but what type of particles are carrying it — which is the key determinant of cardiovascular risk. Subfraction testing is most valuable for people with borderline standard lipid results, metabolic syndrome, diabetes, or a family history of premature heart disease where standard panels may underestimate risk.

The cholesterol ratio compares total cholesterol to HDL cholesterol (total cholesterol ÷ HDL). Because HDL is cardioprotective while total cholesterol includes all lipoprotein particles, this ratio captures the balance between atherogenic and protective cholesterol in a single number.

A cholesterol ratio below 4.0 is generally considered low risk; above 5.0 indicates elevated cardiovascular risk; above 6.0 indicates high risk. The ratio is useful because it incorporates HDL — meaning a high total cholesterol with very high HDL may actually carry low risk, while a borderline total cholesterol with very low HDL may carry significant risk. Australian cardiovascular guidelines use this ratio alongside absolute lipid values for risk stratification.

Creatine kinase (CK) is an enzyme found in high concentrations in muscle cells, including the heart. It catalyses the conversion of creatine and ATP to phosphocreatine, providing rapid energy for muscle contraction. When muscle cells are damaged, CK leaks into the bloodstream and its level rises proportionally to the degree of injury.

CK is used to investigate conditions causing muscle damage including rhabdomyolysis, myopathies, muscular dystrophies, inflammatory muscle disease, and statin-associated muscle toxicity. CK-MB, a cardiac-specific isoenzyme, rises in myocardial infarction — though troponin has largely superseded CK-MB for cardiac diagnosis. Very high CK from skeletal muscle breakdown can cause acute kidney injury due to myoglobin release.

Homocysteine is a sulphur-containing amino acid formed during the metabolism of methionine — an essential amino acid obtained from dietary protein. It is normally converted to cysteine or remethylated back to methionine through pathways that require vitamins B6, B12, and folate as cofactors.

Elevated homocysteine (hyperhomocysteinaemia) damages the endothelium (the inner lining of blood vessels), promotes oxidative stress, impairs nitric oxide function, and increases platelet aggregation — all contributing to cardiovascular disease. Elevated homocysteine is an independent risk factor for heart attack, stroke, and peripheral artery disease, yet is routinely missed in standard cardiovascular assessments. It is also associated with MTHFR gene variants, B12 and folate deficiency, kidney disease, and hypothyroidism.

LDH-1 is the first and most cardiac-specific isoenzyme of lactate dehydrogenase, found predominantly in the heart muscle and red blood cells. In a normal blood sample, LDH-2 is the dominant isoenzyme. Following a myocardial infarction, LDH-1 rises significantly — and when LDH-1 exceeds LDH-2 (the 'flipped' LDH pattern), it is a highly suggestive finding for cardiac damage.

While high-sensitivity troponin has become the primary cardiac biomarker in emergency settings, LDH-1 retains clinical utility in situations where troponin measurement is unavailable, in late presentations after myocardial infarction (when troponin may have normalised but LDH remains elevated), and in the assessment of haemolytic conditions where red blood cell destruction also releases LDH-1.

Myoglobin is an oxygen-binding protein found in skeletal and cardiac muscle cells, where it stores oxygen for use during muscular contraction. When muscle cells are injured, myoglobin is rapidly released into the bloodstream — it is one of the earliest biomarkers to rise after muscle damage.

Myoglobin rises within 1–3 hours of muscle injury, peaks at 8–12 hours, and returns to normal within 24 hours — making it a sensitive early marker of muscle damage. In the context of rhabdomyolysis (severe muscle breakdown), myoglobin levels can become extremely high and cause acute kidney injury when it is filtered and deposits in kidney tubules. Myoglobin is also used as a non-specific early marker of myocardial infarction, though troponin is preferred for cardiac-specific diagnosis.

LDH-3 is the third isoenzyme of lactate dehydrogenase, found predominantly in the lungs, lymphoid tissue, platelets, pancreas, and spleen. It is the isoenzyme most closely associated with lung and lymphoid tissue injury, making it the most relevant LDH isoenzyme in haematological malignancies and pulmonary conditions.

In haematological cancers such as lymphoma and leukaemia, LDH-3 (and LDH-4) are typically the most elevated isoenzymes because lymphoid cells and the lymph nodes, spleen, and bone marrow are involved. LDH-3 elevation also occurs in lung disease, pulmonary embolism, and platelet disorders.

HDL (high-density lipoprotein) cholesterol is often called the 'good' cholesterol because it plays a protective role in cardiovascular health. HDL particles collect excess cholesterol from the artery walls and peripheral tissues and transport it back to the liver for reprocessing or excretion — a process known as reverse cholesterol transport.

Higher HDL levels are associated with reduced cardiovascular risk. Low HDL (below 1.0 mmol/L in men and 1.3 mmol/L in women) is an independent risk factor for heart disease and is strongly associated with insulin resistance, metabolic syndrome, obesity, smoking, and a sedentary lifestyle. Exercise, moderate alcohol consumption, and omega-3 fatty acids are among the most effective ways to raise HDL.

HDL lipid subfractions provide a detailed breakdown of HDL particles beyond total HDL cholesterol. HDL is not a single particle type — it exists as multiple subclasses of different sizes, densities, and compositions, with varying degrees of cardioprotective function.

Larger, more buoyant HDL-2 particles are generally considered most cardioprotective, while smaller, denser HDL-3 particles are less effective at reverse cholesterol transport. Total HDL measurement can be misleading — some individuals with high total HDL may have predominantly dysfunctional HDL subfractions. HDL subfraction testing is part of advanced lipid panels used in cardiovascular risk assessment beyond standard lipid profiles.

LDL-1 is the largest and least dense of the LDL particle subfractions. Large, buoyant LDL particles are generally considered less atherogenic than the smaller, denser LDL particles — they are more readily cleared from the circulation and are less prone to oxidation and entry into arterial walls.

People with predominantly large LDL particles (pattern A) typically have a lower cardiovascular risk profile than those with predominantly small dense LDL particles (pattern B), even at similar total LDL concentrations. LDL-1 measurement is part of advanced lipid subfraction testing and helps characterise the individual's LDL particle distribution.

LDL-2 is a mid-sized LDL particle subfraction — larger than the most atherogenic small dense LDL particles but smaller than LDL-1. It occupies an intermediate position in terms of cardiovascular risk and atherogenicity.

LDL-2 is assessed as part of comprehensive lipid subfraction testing alongside LDL-1 and the small dense LDL particles (sdLDL 1–7). Understanding the distribution of LDL particle sizes provides a more nuanced cardiovascular risk assessment than total LDL cholesterol alone — particularly important for individuals with borderline LDL levels where particle size determines whether the risk is elevated or not.

LDL (low-density lipoprotein) cholesterol is the primary carrier of cholesterol from the liver to peripheral tissues. Often called 'bad' cholesterol, LDL particles — particularly when oxidised — can penetrate the arterial wall and trigger the inflammatory cascade that leads to atherosclerotic plaque formation, arterial narrowing, and ultimately heart attack and stroke.

LDL cholesterol is the primary treatment target in cardiovascular risk management. Australian guidelines recommend LDL below 2.0 mmol/L for high-risk individuals and below 1.8 mmol/L for those with established cardiovascular disease. However, LDL alone does not capture the full risk — particle number (ApoB) and particle size (subfraction testing) provide more complete risk stratification, particularly when LDL appears borderline.

The LDL/HDL ratio compares the level of 'bad' cholesterol (LDL) to 'good' cholesterol (HDL) in the blood. Because HDL works to counteract the harmful effects of LDL, the balance between them is more informative than either measurement alone. A lower ratio indicates a healthier cholesterol profile; a higher ratio indicates greater cardiovascular risk.

An LDL/HDL ratio below 2.0 is generally considered optimal for cardiovascular health. A ratio above 3.0–3.5 is associated with significantly increased risk. This ratio is useful because it captures both sides of the equation — it will flag elevated risk when LDL is high, HDL is low, or both. It complements total cholesterol and the cholesterol ratio in comprehensive cardiovascular risk assessment.

LDL Mid A represents a specific intermediate LDL particle subfraction that sits between the large buoyant LDL particles and the smaller more atherogenic particles. It is part of the detailed particle size distribution measured in comprehensive lipid subfraction testing.

Lipid subfraction testing maps the full spectrum of LDL particle types, from the largest and least harmful (LDL-1) through mid-range particles (LDL Mid A, B, C and LDL-2) to the most dangerous small dense LDL particles. This detailed characterisation is valuable for patients with metabolic syndrome, diabetes, or borderline cardiovascular risk where standard LDL may underestimate true risk.

LDL Mid B is an intermediate-small LDL particle subfraction, sitting between the mid-large and the small dense LDL particles. As particles become smaller and denser along the LDL spectrum, they become progressively more atherogenic — more capable of penetrating the arterial wall and contributing to plaque.

Elevated LDL Mid B alongside elevated small dense LDL particles indicates a shift in the LDL particle profile toward greater atherogenicity, even when total LDL appears normal or mildly elevated. This pattern is often seen in metabolic syndrome, type 2 diabetes, and insulin resistance, where the liver produces smaller, denser LDL particles.

LDL Mid C is a specific intermediate-to-small LDL particle subfraction measured in comprehensive lipid subfraction analysis. It sits between larger LDL mid particles and the smallest, most atherogenic small dense LDL (sdLDL) particles. As particles decrease in size along the LDL spectrum, they become progressively more atherogenic.

LDL Mid C is part of the detailed particle size distribution that helps characterise whether a person has a predominantly large buoyant (low-risk, pattern A) or small dense (high-risk, pattern B) LDL profile. This is particularly relevant in people with metabolic syndrome, type 2 diabetes, or insulin resistance where standard LDL measurements may underestimate true cardiovascular risk.

LDL Peaks is a summary measure derived from LDL subfraction analysis that identifies the dominant LDL particle pattern. It indicates whether the LDL distribution peaks in the large, buoyant range (pattern A) or in the small, dense range (pattern B). Pattern B is associated with approximately three times the cardiovascular risk of pattern A at any given total LDL cholesterol level.

Pattern A is characterised by large, buoyant LDL particles that are less prone to oxidation and arterial wall penetration. Pattern B is characterised by small, dense LDL particles that accumulate in arterial walls more readily, contribute to plaque formation, and are more susceptible to oxidative modification. The LDL Peaks result provides a clear clinical summary of the overall atherogenicity of the LDL pool.

Lipoprotein(a), or Lp(a), is a lipoprotein particle structurally similar to LDL but with an additional apolipoprotein(a) protein attached. This structure gives Lp(a) both atherogenic and prothrombotic properties, making elevated Lp(a) a potent cardiovascular risk factor.

Lp(a) is 80-90% genetically determined and largely resistant to lifestyle modification. About 20-25% of Australians have elevated Lp(a). This elevation carries substantially higher lifetime cardiovascular risk independent of traditional risk factors including LDL cholesterol.

Mean lipoprotein particle size reflects the average size of lipoprotein particles (LDL, HDL, VLDL) circulating in the blood. Larger average particle size is generally associated with lower cardiovascular risk; smaller average size indicates a shift toward the atherogenic small dense pattern.

This measure is most clinically meaningful for LDL particle size, where smaller particles are more atherogenic. It can identify individuals with hidden cardiovascular risk whose standard lipid panels appear normal but whose particle pattern is unfavourable.

Non-HDL cholesterol is calculated by subtracting HDL cholesterol from total cholesterol. It represents the combined cholesterol content of all the atherogenic lipoprotein particles — LDL, VLDL, IDL, and Lp(a) — making it a broader and arguably more complete measure of atherogenic cholesterol than LDL alone.

Non-HDL cholesterol has several advantages over LDL: it does not require fasting, it captures all atherogenic particles including triglyceride-rich remnant particles, and it may be a better predictor of cardiovascular risk than LDL alone. It is increasingly recommended in cardiovascular risk guidelines as a primary treatment target alongside or instead of LDL, particularly in people with high triglycerides where calculated LDL can be unreliable.

Small dense LDL-1 (sdLDL-1) is the first of the small dense LDL subfractions — particles that are smaller and denser than standard LDL. Small dense LDL particles are more atherogenic than large LDL for several reasons: they penetrate arterial walls more easily, they are more susceptible to oxidation, they have a longer half-life in the circulation, and they have reduced affinity for LDL receptors.

Elevated sdLDL particles are a hallmark of the atherogenic dyslipidaemia associated with insulin resistance, metabolic syndrome, type 2 diabetes, and high triglycerides. sdLDL-1 is the largest of the small dense particles — still dangerous but less so than sdLDL-4 through 7. Its elevation alongside other small dense particles indicates a shift toward Pattern B lipid phenotype.

Small dense LDL-2 (sdLDL-2) is the second smallest-density LDL subfraction measured in comprehensive lipid panel testing. Like all small dense LDL particles, sdLDL-2 is more atherogenic than larger LDL-1 and LDL-2 particles — it penetrates the arterial intima more readily, is more prone to oxidation, and contributes more significantly to plaque development.

Elevated sdLDL-2 alongside other small dense LDL subfractions reflects a Pattern B LDL phenotype, characteristic of individuals with insulin resistance, type 2 diabetes, or metabolic syndrome. Identifying this pattern allows for targeted interventions — low-carbohydrate dietary approaches and triglyceride-lowering medications tend to shift the LDL particle distribution back toward larger, less harmful particles.

Small dense LDL-3 (sdLDL-3) represents a progressively smaller and more dangerous LDL particle subfraction. As particles decrease in size through the sdLDL series, they become more atherogenic — more capable of entering and being retained within the arterial wall, where they trigger inflammation and plaque formation.

Elevation of sdLDL-3 and beyond (sdLDL-4 through 7) is associated with the most significant cardiovascular risk in the small dense LDL series. These particles are a particularly strong predictor of risk in individuals whose total LDL appears acceptable — a phenomenon sometimes referred to as the 'LDL paradox', where individuals with standard LDL levels continue to have heart attacks because their particle pattern is atherogenic.

Small dense LDL-4 (sdLDL-4) is among the most atherogenic LDL subfractions, representing particles that are both very small and very dense. These particles have a dramatically higher ability to penetrate the arterial intima, evade LDL receptor clearance, and undergo oxidation — the key initiating events in atherosclerotic plaque formation.

Elevated sdLDL-4, along with sdLDL-5, 6, and 7, represents the most clinically concerning pattern in lipid subfraction testing. The presence of these particles explains why some individuals develop coronary artery disease despite 'normal' LDL cholesterol levels — their particles are simply more dangerous than what standard tests detect. Measuring sdLDL-4 is particularly valuable for refining cardiovascular risk in high-stakes clinical decisions.

Small dense LDL-5 (sdLDL-5) is one of the smallest and most pathogenic LDL particle subfractions. At this level of particle density and size, the atherogenic properties are at their most pronounced — these particles are extremely prone to oxidation, resist receptor-mediated clearance, and penetrate and are retained in the arterial wall with greatest efficiency.

The small dense LDL pattern (sdLDL-5 through 7) is the lipoprotein signature of severe insulin resistance and advanced metabolic dysfunction. Its presence alongside high triglycerides and low HDL forms the classic atherogenic dyslipidaemia triad — a pattern that carries cardiovascular risk disproportionate to what standard lipid panels suggest.

Small dense LDL-6 (sdLDL-6) represents one of the smallest and most pathogenic LDL particle subfractions measured in advanced lipid testing. At this level of particle density and size, atherogenic properties are near their maximum — these particles penetrate the arterial intima with exceptional ease, resist LDL receptor-mediated clearance, and undergo oxidative modification rapidly after arterial wall entry.

The presence of elevated sdLDL-6 alongside sdLDL-5 and sdLDL-7 defines the most severe form of small dense LDL dyslipidaemia, closely associated with very advanced metabolic dysfunction. sdLDL-6 is part of the integrated total sdLDL assessment that captures cumulative atherogenic particle burden.

Small dense LDL-7 (sdLDL-7) is the smallest and densest LDL particle subfraction measured in comprehensive lipid testing. It represents the extreme end of LDL particle atherogenicity — these particles have the greatest capacity to cause arterial damage of any LDL subfraction.

Elevation of sdLDL-7 is a strong predictor of cardiovascular events and is particularly concerning in individuals who appear to have acceptable standard lipid results. Measurement of total small dense LDL (combining sdLDL-1 through 7) provides a single clinically actionable number that summarises the full atherogenic burden from this particle class, and its measurement is increasingly incorporated into advanced cardiovascular risk protocols.

The TG/HDL ratio compares triglyceride levels to HDL cholesterol. It is one of the simplest and most powerful surrogate markers for insulin resistance and atherogenic dyslipidaemia. When triglycerides are high and HDL is low — the classic metabolic syndrome pattern — the ratio rises and cardiovascular risk increases substantially.

A TG/HDL ratio below 1.0 (in mmol/L units) is considered optimal and is associated with predominantly large buoyant LDL particles (Pattern A). A ratio above 1.7–2.0 suggests insulin resistance and is associated with a shift toward the more dangerous small dense LDL Pattern B. The ratio above 2.0 strongly predicts the presence of small dense LDL even without measuring subfractions directly.

Total cholesterol is the sum of all cholesterol fractions in the blood: LDL cholesterol, HDL cholesterol, VLDL cholesterol, and other minor components. Cholesterol is a waxy fat essential for cell membrane structure, steroid hormone synthesis, bile acid production, and vitamin D synthesis. It is carried in the blood by lipoprotein particles.

Total cholesterol alone is a limited cardiovascular risk marker because it does not distinguish between atherogenic (LDL, VLDL) and protective (HDL) fractions. A high total cholesterol driven by high HDL carries a very different risk profile to the same total driven by high LDL. For this reason, a full lipid panel including LDL, HDL, triglycerides, and non-HDL cholesterol is required for meaningful cardiovascular risk assessment.

IDL (intermediate-density lipoprotein) particles form during the conversion of VLDL to LDL. They are atherogenic remnant lipoproteins that can be directly taken up by arterial walls. IDL is not captured by standard LDL tests and is underestimated in routine cardiovascular risk assessment.

Elevated IDL is particularly common in insulin resistance, metabolic syndrome, type III hyperlipoproteinaemia, and hypothyroidism. It represents atherogenic particle burden beyond what standard lipid panels detect.

Total LDL lipid subfractions breaks down LDL cholesterol into its component particle subtypes — from the largest and least harmful LDL-1 through the progressively smaller and more atherogenic LDL-2, LDL Mid A, LDL Mid B, LDL Mid C, and the small dense LDL subfractions (sdLDL-1 through 7). The total LDL subfraction panel provides the complete LDL particle size distribution.

This comprehensive view transforms a single LDL number into a detailed risk profile. Two individuals with identical LDL cholesterol can have dramatically different cardiovascular risk depending on whether their LDL is predominantly large buoyant (Pattern A, lower risk) or small dense (Pattern B, higher risk). Total LDL subfractions is the gold standard for identifying atherogenic dyslipidaemia.

Total small dense LDL is the combined measurement of IDL and all sdLDL subfractions (sdLDL-1 through sdLDL-7). It quantifies the total burden of the most atherogenic lipoproteins — the particles that most effectively penetrate arterial walls, resist clearance, and accumulate in plaques.

This integrated measure is particularly valuable in metabolic syndrome, where Pattern B atherogenic dyslipidaemia can exist with apparently normal standard LDL cholesterol.

Triglycerides are the most common form of fat found in the body and in food. After eating, the body converts unused calories — particularly from carbohydrates and alcohol — into triglycerides, which are stored in fat cells and released for energy between meals. In the bloodstream, triglycerides are carried within VLDL and chylomicron particles.

Elevated triglycerides (hypertriglyceridaemia) are strongly associated with insulin resistance, metabolic syndrome, type 2 diabetes, obesity, high refined carbohydrate intake, alcohol consumption, and certain medications. Very high triglycerides (above 10 mmol/L) increase the risk of acute pancreatitis. Triglycerides must be measured fasting for accurate results, as they rise transiently after every meal.

Triglycerides lipid subfractions characterise triglyceride content across different lipoprotein classes (VLDL, IDL, LDL, HDL), providing mechanistic insight into how triglyceride burden is packaged. Standard triglyceride testing measures total circulating triglycerides but does not reveal which particles carry them.

Troponin is a cardiac-specific protein released when heart muscle is damaged. It is the gold standard biomarker for diagnosing myocardial infarction. High-sensitivity troponin assays detect cardiac injury within 1-3 hours of chest pain, enabling rapid rule-in or rule-out of heart attack in emergency settings.

Troponin elevation is not exclusive to heart attacks. Myocarditis, pulmonary embolism, sepsis, heart failure, and even strenuous exercise can elevate troponin. The pattern of rise and fall — plus clinical context — determines whether the cause is acute MI or another condition.

VLDL (very low-density lipoprotein) lipid subfractions characterise the size and distribution of VLDL particles produced by the liver. VLDL particles carry triglycerides from the liver to peripheral tissues for energy use or fat storage. Like LDL, VLDL is not a single particle type — it exists as large, medium, and small particles with different metabolic fates and atherogenic potential.

Large VLDL particles are produced in excess under conditions of high caloric intake, high refined carbohydrate consumption, and insulin resistance. Elevated large VLDL drives down HDL and promotes the formation of small dense LDL — the key mechanism of atherogenic dyslipidaemia. VLDL subfraction testing quantifies this upstream driver and provides mechanistic insight into why an individual's LDL particle profile may be shifting toward a more dangerous pattern.

Anti-DGP IgG (deamidated gliadin peptide IgG antibody) is a blood test used in the diagnosis of coeliac disease. It detects IgG-class antibodies produced against deamidated forms of gliadin — a component of gluten. Unlike standard gliadin antibody tests, anti-DGP antibodies target modified gliadin peptides that more specifically reflect the immune response occurring in coeliac disease.

Anti-DGP IgG is most valuable in people with IgA deficiency, which affects approximately 1 in 600 people. Because the standard coeliac screening test (tTG IgA) relies on IgA antibodies, it gives a false-negative result in IgA-deficient individuals even when coeliac disease is present. Anti-DGP IgG provides an IgA-independent alternative, ensuring coeliac disease is not missed in this group. It is also used in children under two years, in whom tTG IgA may be less reliable.

Anti-parietal cell antibodies (APCA) are autoantibodies directed against the H+/K+-ATPase proton pump on gastric parietal cells. Parietal cells are responsible for producing both hydrochloric acid and intrinsic factor, a protein essential for vitamin B12 absorption in the small intestine. When the immune system attacks these cells, it causes autoimmune atrophic gastritis.

Progressive parietal cell destruction reduces stomach acid production and, critically, reduces intrinsic factor output. Without intrinsic factor, vitamin B12 cannot be absorbed from food, eventually causing pernicious anaemia and B12 deficiency with neurological consequences. APCA are found in up to 90% of people with pernicious anaemia but are also present in a significant proportion of older adults and people with other autoimmune conditions without pernicious anaemia.

Intestinal alkaline phosphatase (intestinal ALP) is an isoenzyme of alkaline phosphatase produced specifically by cells lining the small intestine, particularly in the duodenum and jejunum. It plays a role in fat absorption and maintaining intestinal barrier function. After a fatty meal, intestinal ALP is released into the bloodstream along with absorbed lipids.

Intestinal ALP is one of the four main ALP isoenzymes (alongside bone, liver, and placental ALP) measured in ALP isoenzyme analysis. It helps identify the intestinal origin of an elevated total ALP result and provides information about intestinal lipid transport and epithelial function. It is more commonly elevated in people with blood group B or O who are secretors.

Tissue transglutaminase IgA (tTG IgA) is the gold-standard blood test for coeliac disease. It detects IgA-class antibodies directed against tissue transglutaminase 2, an enzyme that modifies gliadin — a component of gluten — into a form that triggers an immune response in people with coeliac disease. The antibody is produced in the small intestinal lining as part of the immune attack on intestinal tissue.

In coeliac disease, ingestion of gluten triggers the immune system to produce tTG IgA antibodies and attack the intestinal lining, causing progressive damage to the villi — small finger-like projections responsible for nutrient absorption. tTG IgA is the single most sensitive and specific blood test for coeliac disease in IgA-sufficient individuals, with sensitivity above 90% and specificity above 95% when combined with compatible symptoms.

Semen concentration measures the number of sperm cells per millilitre of ejaculate. It is one of the key parameters of a semen analysis (spermogram) and reflects the ability of the testes to produce sperm. Along with total motility and morphology, concentration is used to assess male fertility potential.

The WHO 2021 reference value for semen concentration is 16 million sperm per millilitre as a lower reference limit (5th percentile of fertile men). Concentrations below this (oligospermia) are associated with reduced fertility. Severely low concentration (below 5 million/mL) is called severe oligospermia; absence of sperm is azoospermia, which requires specialist urology investigation.

Semen liquefaction refers to the process by which semen transitions from a gel-like coagulum (immediately after ejaculation) to a liquid state. Normal semen liquefies within 15-30 minutes due to prostatic enzymes (particularly PSA) breaking down the seminal vesicle proteins that form the initial coagulum. This liquefaction is essential for sperm to be released and swim freely.

Incomplete or delayed liquefaction (beyond 60 minutes) can impair sperm motility and fertilising capacity, as sperm remain trapped in the gel matrix. This is assessed as part of a complete semen analysis and may indicate prostatic or seminal vesicle dysfunction affecting accessory gland secretion.

Sperm morphology assesses the size and shape of sperm cells according to strict Kruger criteria. A normal sperm has an oval head, well-defined acrosome covering 40-70% of the head, absence of midpiece or tail defects, and normal cytoplasmic droplets. Only sperm meeting all these criteria are classified as morphologically normal.

Even in fertile men, the majority of sperm have structural abnormalities under strict criteria — the WHO 2021 reference value is 4% as the lower limit for normal forms. Poor morphology (teratozoospermia) is associated with reduced fertilisation rates in IVF, poor embryo quality, and increased DNA fragmentation. Morphology provides complementary information alongside concentration and motility.

Progressive motility measures the percentage of sperm that swim forward in a straight line or large circles (grades A and B motility). It is distinct from total motility, which includes sperm moving in any direction including in place. Progressive motility directly reflects the sperm's ability to navigate the female reproductive tract and reach the egg for fertilisation.

The WHO 2021 lower reference limit for progressive motility is 30% (5th percentile of fertile men). Low progressive motility (asthenozoospermia) is associated with reduced natural conception rates and lower success rates in IUI (intrauterine insemination). Progressive motility is considered the most functionally relevant motility measure for natural fertility.

Total motility measures the percentage of all sperm showing any movement, including progressive (forward), non-progressive (circular), and sluggish movement. The WHO 2021 lower reference limit is 42%. A high proportion of immotile sperm may indicate necrozoospermia or mitochondrial dysfunction.

Semen volume measures the total amount of fluid ejaculated per sample in millilitres. Semen is produced by multiple accessory glands: the seminal vesicles contribute about 65-70% of volume, the prostate gland contributes about 25-30%, and the bulbourethral glands (Cowper's glands) contribute a small fraction. The testes and epididymis contribute the sperm cells but very little volume.

The WHO 2021 lower reference limit for semen volume is 1.4 mL. Very low volume (hypospermia, below 1.4 mL) can indicate ejaculatory dysfunction, retrograde ejaculation, obstruction of the ejaculatory ducts, or hormonal hypogonadism. Very high volume can dilute sperm concentration. Volume directly affects total sperm count per ejaculate.

MTHFR (methylenetetrahydrofolate reductase) gene testing identifies common variants in the MTHFR gene, particularly C677T and A1298C. These variants reduce the efficiency of the MTHFR enzyme, which converts folate into its active form (5-methyltetrahydrofolate, or 5-MTHF) required for the methylation cycle, homocysteine remethylation, and DNA synthesis.

The C677T homozygous variant (two copies) reduces enzyme activity by 60-70% and is associated with elevated homocysteine (particularly when folate intake is low), increased neural tube defect risk in pregnancy, and possible cardiovascular risk. However, MTHFR variants are very common (about 10-15% of people carry two C677T copies) and their clinical significance in the absence of elevated homocysteine is debated. Testing provides guidance for folate supplementation strategy.

Aluminium is the most abundant metal in the Earth's crust and humans are exposed to small amounts through food, water, cookware, antiperspirants, antacids, and occupational environments. At low levels the body excretes aluminium efficiently through the kidneys. At elevated levels — typically from dialysis, high-dose antacid use, or significant occupational exposure — aluminium can accumulate in the blood, bones, and brain, where it is toxic.

The kidneys are central to aluminium excretion, meaning people with chronic kidney disease (CKD) are at significantly higher risk of accumulation. Historically, aluminium toxicity was a serious complication in dialysis patients who were exposed to aluminium-contaminated dialysate. Modern dialysis uses purified water, but aluminium-containing phosphate binders are still occasionally used in CKD, making monitoring important.

Arsenic is a naturally occurring metalloid found in soil, water, and food. Humans are exposed through contaminated drinking water (a significant issue in some parts of Asia, South America, and regional Australia), consumption of rice and seafood (which can contain organic arsenic), and occupational exposure in mining, smelting, and pesticide manufacturing. Two forms exist: inorganic arsenic (more toxic, found in water and soil) and organic arsenic (less toxic, found in seafood).

Blood arsenic testing measures total arsenic concentration in the bloodstream and reflects recent exposure rather than cumulative body burden. Chronic low-level exposure to inorganic arsenic is a known carcinogen associated with bladder, lung, and skin cancers, as well as cardiovascular disease, peripheral neuropathy, and skin changes (hyperkeratosis, Mees' lines on nails). Urine arsenic measurement provides a better assessment of ongoing exposure; blood arsenic reflects acute recent intake.

Cadmium is a toxic heavy metal with no known biological role in humans. It is found naturally in the environment and is released in higher concentrations through industrial processes including mining, smelting, battery manufacturing, and phosphate fertiliser production. Humans are primarily exposed through cigarette smoking (tobacco plants accumulate cadmium from soil), food (particularly rice, vegetables, and organ meats from cadmium-contaminated soils), and occupational settings.

Cadmium accumulates in the kidneys, liver, and bones over decades. Because its biological half-life is 10–30 years, even modest chronic exposure leads to gradual body burden accumulation. At elevated concentrations, cadmium causes kidney tubular damage (reducing the ability to reabsorb proteins and phosphate), bone demineralisation (itai-itai disease, first identified in Japan), and is classified as a Group 1 carcinogen, associated with lung, kidney, and prostate cancer.

Coronary risk assessment from lipid subfraction analysis evaluates the balance between atherogenic and cardioprotective lipoprotein particles. Rather than relying on total cholesterol alone, coronary risk profiling examines specific lipoprotein subfractions for a more accurate picture of cardiovascular risk.

An LDL pattern dominated by small, dense particles (pattern B) carries approximately three times the cardiovascular risk of large buoyant particles (pattern A) at the same total LDL level. This analysis is valuable for people with borderline standard cholesterol where LDL measurements may significantly underestimate true cardiovascular risk.

Gold (Au) is a heavy metal with no known biological role in the body. Blood gold testing is used to monitor therapeutic gold levels in people taking gold-based medications for inflammatory conditions, and to assess for gold toxicity in those with significant occupational or medical exposure.

Gold compounds, particularly injectable sodium aurothiomalate and oral auranofin, were historically used as disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis. While largely superseded by modern biologic therapies, some patients remain on gold therapy. At therapeutic doses, gold can cause side effects including skin rashes, kidney damage (proteinuria), and rarely blood disorders, making monitoring important.

Lead (Pb) is a toxic heavy metal with no known biological role in the human body. Blood lead testing measures the concentration of lead in whole blood, which reflects recent and ongoing exposure. Lead is a potent neurotoxin, particularly damaging to the developing nervous system of children, but also harmful to adults at elevated concentrations.

Lead accumulates in bone over years, creating a long-term reservoir that can release lead back into circulation during pregnancy, breastfeeding, menopause, and periods of bone resorption. Even low blood lead levels previously considered safe are now associated with cognitive decline, hypertension, and reduced kidney function in adults. There is no established safe blood lead level.

Lithium is a mood-stabilising medication used primarily for bipolar disorder. Because lithium has a narrow therapeutic window, regular blood level monitoring is essential. Too little provides no clinical benefit; too much causes toxicity. Blood lithium testing measures the serum concentration to ensure levels remain within the therapeutic range.

Lithium toxicity can range from mild (tremor, thirst, polyuria, nausea, diarrhoea) to severe (confusion, ataxia, seizures, cardiac arrhythmias, and kidney failure). Kidney function and thyroid function are also monitored in people on lithium, as long-term therapy can impair both. The standard monitoring target is a 12-hour post-dose trough level.

Mercury (Hg) is a toxic heavy metal with no beneficial biological role. Blood mercury testing measures the concentration of total mercury in whole blood, primarily reflecting recent or ongoing exposure to methylmercury (from fish consumption) or inorganic mercury (from industrial or dental sources). Methylmercury is the most bioavailable and neurotoxic form.

Mercury is a potent neurotoxin affecting the central and peripheral nervous system, kidneys, and immune system. The developing foetal brain is particularly vulnerable. Elevated blood mercury from regular high fish consumption (particularly large predatory fish such as shark, swordfish, and orange roughy) is the most common cause in developed countries including Australia.

Whole blood mercury testing measures total mercury (organic and inorganic) in whole blood rather than serum. It is the preferred specimen for detecting methylmercury exposure from fish consumption, as methylmercury partitions preferentially into red blood cells. Whole blood mercury provides a more comprehensive picture than serum mercury alone.

Like standard blood mercury testing, whole blood mercury reflects exposure over approximately the preceding 3 months due to methylmercury's half-life in red cells. It is used in occupational health monitoring, dietary assessment of mercury exposure, and in the investigation of potential mercury toxicity symptoms.

Nickel is a trace metal with no essential role in humans. Blood nickel testing monitors exposure in workers in nickel mining, refining, electroplating, and stainless steel manufacturing, where chronic exposure is associated with lung and nasal cancer risk.

Nickel is also the most common cause of contact dermatitis from jewellery and metal items. Blood nickel levels are occasionally measured in people with nickel allergy and suspected systemic reactions, or after joint replacement with nickel-containing metal-on-metal alloys.

Strontium is a naturally occurring trace element chemically similar to calcium. It is found in small amounts in bone and water, and has been used medicinally at high doses (strontium ranelate) to increase bone density in osteoporosis. However, strontium ranelate was withdrawn from most markets due to cardiovascular concerns. Strontium in bone can interfere with DEXA bone density measurements, creating falsely reassuring results.

Blood strontium testing is used to monitor whether strontium supplementation is at a safe level, to detect excessive exposure, and to assess whether bone-building supplements containing strontium are causing accumulation. Very high strontium exposure from industrial sources or excessive supplementation can be toxic.

ACTH is a critical hormone produced by the pituitary gland, which is often called the "master gland" because it regulates various other glands in the body. ACTH stimulates the adrenal glands, located on top of the kidneys, to produce cortisol. Cortisol is essential for the body's response to stress, regulating metabolism, and maintaining blood pressure.

Think of ACTH as the signalman on a railway, directing the adrenal glands when to release cortisol to keep the body's "trains" running smoothly. If cortisol levels are too low, ACTH production ramps up to stimulate the adrenals to produce more; if cortisol is too high, ACTH production decreases, creating a feedback loop that keeps the system balanced. Monitoring ACTH provides insights into how well this system is functioning and can reveal disruptions in this hormonal balance.

Anti-Müllerian hormone (AMH) is produced by small follicles in the ovaries and is one of the most reliable indicators of a woman's ovarian reserve — the number and quality of eggs remaining. Unlike other hormonal markers, AMH remains relatively stable throughout the menstrual cycle, making it a convenient and consistent test that can be taken at any time of the month.

AMH levels naturally decline with age as the pool of available follicles shrinks. A higher AMH indicates a larger ovarian reserve, while a lower AMH suggests fewer eggs remain. It is widely used in fertility assessment, IVF planning, and investigating conditions such as polycystic ovarian syndrome (PCOS) and premature ovarian insufficiency (POI).

Androstenedione is a steroid hormone produced by the adrenal glands and the gonads — the testes in men and the ovaries in women. It sits at a key junction in the hormonal production pathway, serving as a direct precursor to both testosterone and oestrogen. Because of this central position, its levels can influence the balance of sex hormones throughout the body.

In women, elevated androstenedione is one of the most common hormonal findings in polycystic ovarian syndrome (PCOS) and congenital adrenal hyperplasia, and can contribute to symptoms such as irregular periods, acne, and excess hair growth. In men, it contributes to the overall androgen pool alongside testosterone and DHEAS.

Bioavailable testosterone refers to the fraction of total testosterone in the blood that is not tightly bound to sex hormone-binding globulin (SHBG) and is therefore available to enter cells and exert biological effects. It includes both free testosterone (completely unbound) and testosterone loosely bound to albumin, which can readily dissociate and enter tissues.

Approximately 98% of total testosterone circulates bound to proteins — about 44% to albumin and 54% to SHBG. SHBG-bound testosterone is tightly bound and cannot enter cells. Only the remaining 2% (free) plus albumin-bound testosterone is biologically active. Because SHBG levels vary significantly with age, obesity, liver disease, and medications, total testosterone can be misleading — bioavailable testosterone corrects for this and reflects what the body's tissues can actually use.

Calcitonin is a hormone produced and secreted by C-cells (parafollicular cells) in the thyroid gland. Its primary role is to lower blood calcium levels by inhibiting the activity of osteoclasts — the cells that break down bone — and by reducing calcium reabsorption in the kidneys. It acts as a counterbalance to parathyroid hormone (PTH), which raises calcium.

In clinical practice, calcitonin testing is most commonly used as a tumour marker for medullary thyroid carcinoma (MTC), a type of thyroid cancer that arises from C-cells. Significantly elevated calcitonin is a sensitive and specific marker for MTC and is used both for diagnosis and post-treatment monitoring.

DHEAS (dehydroepiandrosterone sulphate) is a steroid hormone produced almost exclusively by the adrenal glands. It is the sulphated, storage form of DHEA and serves as a reservoir from which the body can produce other sex hormones including testosterone and oestrogen in peripheral tissues.

DHEAS levels peak in the mid-20s and decline steadily with age — by the age of 70, levels are typically 20–30% of their peak. This age-related decline has driven significant research interest in DHEAS as a marker of biological age and adrenal reserve. Clinically, it is used to investigate adrenal tumours, PCOS, premature adrenal insufficiency, and to assess the contribution of adrenal androgens to symptoms such as acne, hair loss, and low libido.

Dihydrotestosterone (DHT) is a potent androgen hormone formed from testosterone by the enzyme 5-alpha reductase. It is approximately 2–3 times more biologically active than testosterone and binds to androgen receptors with much greater affinity. DHT plays a critical role in the development of male sexual characteristics during foetal development and at puberty.

In adults, DHT is most strongly associated with the prostate gland and hair follicles. Elevated DHT is a primary driver of benign prostatic hyperplasia (BPH) and male pattern baldness (androgenetic alopecia). In women, excess DHT can contribute to female pattern hair loss, acne, and hirsutism. Testing DHT is relevant when investigating these conditions or assessing the effects of 5-alpha reductase inhibitors such as finasteride.

The Free Androgen Index (FAI) is a calculated ratio that estimates the amount of biologically active androgens — primarily testosterone — available to act on target tissues. It is calculated by dividing total testosterone by SHBG and multiplying by 100. A higher FAI indicates more free androgen activity, while a lower FAI suggests androgens are being heavily bound and inactivated by SHBG.

FAI is particularly useful in women, where it helps identify androgen excess conditions such as PCOS, which can cause irregular periods, acne, and excess hair growth. In men, it is sometimes used alongside free testosterone to assess whether symptoms of low testosterone are related to high SHBG rather than genuinely low testosterone production.

Free testosterone is the fraction of total testosterone in the blood that is completely unbound — not attached to sex hormone-binding globulin (SHBG) or albumin. It represents approximately 1-3% of total testosterone and is the most biologically active form, able to enter cells directly and bind to androgen receptors to exert its effects on muscle, bone, brain, libido, mood, and energy.

Because SHBG levels vary significantly with age, health status, and medications, total testosterone can be misleading. A person with high SHBG can have normal total testosterone but very low free testosterone, producing symptoms of androgen deficiency. Measuring free testosterone alongside SHBG and total testosterone provides the most complete and clinically accurate picture of androgen status in both men and women.

Follicle-stimulating hormone (FSH) is produced by the anterior pituitary gland and is one of the two primary gonadotropins regulating reproductive function. In women, FSH drives the development of ovarian follicles during the early phase of the menstrual cycle and stimulates oestrogen production. A surge of FSH and LH triggers ovulation at mid-cycle.

In men, FSH acts on the Sertoli cells of the testes to support spermatogenesis. FSH levels are regulated by a negative feedback loop involving oestradiol and inhibin B in women, and inhibin B in men. Rising FSH in women signals that fewer responsive follicles remain, making it a valuable marker of ovarian reserve alongside AMH. In both sexes, abnormal FSH can indicate problems at the level of the pituitary or the gonads.

Gastrin is a peptide hormone produced primarily by G-cells in the stomach lining in response to food, particularly protein. Its main function is to stimulate the secretion of hydrochloric acid by parietal cells in the stomach, which is essential for protein digestion and killing ingested bacteria.

Elevated gastrin levels (hypergastrinaemia) can result from conditions such as Zollinger-Ellison syndrome — caused by a gastrin-secreting tumour — atrophic gastritis, or long-term use of proton pump inhibitors (PPIs). Testing gastrin is useful when investigating unexplained peptic ulcers, chronic diarrhoea, or high acid secretion that doesn't respond to standard treatment.

Growth hormone (GH) is secreted by the anterior pituitary gland in a pulsatile pattern — primarily during deep sleep and exercise. It stimulates growth in children and adolescents, and in adults it continues to regulate body composition, metabolism, bone density, and cardiac function. GH acts directly on tissues and also stimulates the liver to produce IGF-1, which mediates many of its growth-promoting effects.

GH testing is used to investigate both excess and deficiency. In children, GH deficiency causes short stature; in adults, it causes fatigue, reduced muscle mass, increased fat mass, and poor quality of life. Excess GH — typically from a pituitary tumour — causes acromegaly in adults (enlarged hands, feet, and facial features) and gigantism in children. A single GH measurement is rarely diagnostic due to its pulsatile nature; IGF-1 is often used as a more stable surrogate.

17-Hydroxyprogesterone (17-OHP) is a steroid hormone produced primarily by the adrenal glands and — in smaller amounts — by the gonads. It is an intermediate in the biosynthesis of cortisol. When the enzymes responsible for converting 17-OHP to cortisol are deficient or absent — as in congenital adrenal hyperplasia (CAH) — 17-OHP accumulates to very high levels.

CAH due to 21-hydroxylase deficiency is the most common adrenal enzyme disorder and causes elevated 17-OHP, leading to excess androgen production that can cause ambiguous genitalia in newborn girls, early puberty, acne, irregular periods, and infertility. 17-OHP is also tested to assess adrenal function and investigate unexplained androgen excess in adults.

Luteinising hormone (LH) is produced by the anterior pituitary gland and plays a central role in reproduction in both sexes. In women, LH drives the final maturation of ovarian follicles and triggers ovulation — the LH surge is the signal that causes the egg to be released. After ovulation, LH stimulates the corpus luteum to produce progesterone, which prepares the uterine lining for a potential pregnancy.

In men, LH stimulates the Leydig cells in the testes to produce testosterone. Abnormal LH levels can indicate problems at the level of the pituitary gland, hypothalamus, or gonads. High LH with low sex hormones suggests primary gonadal failure, while low LH with low sex hormones suggests a pituitary or hypothalamic cause.

The LH to FSH ratio compares two of the most important pituitary hormones in reproductive health. LH (luteinising hormone) triggers ovulation and stimulates sex hormone production, while FSH (follicle stimulating hormone) drives follicle development and sperm production. In a normal menstrual cycle, FSH tends to be slightly higher than LH in the follicular phase, with LH surging dramatically at ovulation.

An elevated LH to FSH ratio — typically greater than 2:1 or 3:1 in the early follicular phase — is a classic finding in polycystic ovarian syndrome (PCOS). This ratio is not diagnostic on its own but forms part of the hormonal picture when evaluating irregular cycles, absent ovulation, and fertility concerns.

Oestradiol (E2) is the most potent and biologically active form of oestrogen and the primary oestrogen produced by the ovaries during the reproductive years. It plays a fundamental role in female reproductive health — regulating the menstrual cycle, supporting uterine lining development, and maintaining bone density, skin integrity, cardiovascular health, and cognitive function.

In men, oestradiol is produced in smaller amounts through the conversion of testosterone by the enzyme aromatase. While necessary for bone health and libido in men, elevated oestradiol in males can cause gynaecomastia (breast tissue growth) and fertility problems. Oestradiol testing is used across a wide range of clinical situations including cycle monitoring, fertility treatment, investigating menopausal symptoms, and hormonal therapy.

Oestradiol measured by liquid chromatography-mass spectrometry (LCMS) is the gold standard method for oestradiol quantification, offering far greater accuracy and specificity than conventional immunoassay methods — particularly at very low concentrations.

Standard immunoassay oestradiol tests can produce unreliable results in postmenopausal women, men, children, and individuals on hormone therapy — precisely the groups where accurate measurement matters most. LCMS eliminates cross-reactivity with structurally similar hormones and avoids interference from high-dose biotin supplementation. It is the preferred method for anyone requiring precise hormonal assessment, including those on testosterone therapy, hormone replacement therapy, or undergoing IVF monitoring.

Progesterone is a steroid hormone produced primarily by the corpus luteum — the temporary endocrine structure that forms in the ovary after ovulation — and, during pregnancy, by the placenta. Its primary roles are to prepare and maintain the uterine lining for embryo implantation, suppress further ovulation during pregnancy, and support early pregnancy development.

In clinical practice, a mid-luteal progesterone test (taken around day 21 of a 28-day cycle, or 7 days before the expected period) is used to confirm that ovulation has occurred. Low progesterone in the luteal phase is associated with irregular cycles, infertility, and early pregnancy loss. Progesterone is also used in both men and women to balance the effects of oestrogen in hormone replacement therapy.

Prolactin is a hormone produced by the pituitary gland whose primary function is to stimulate breast milk production after childbirth. However, prolactin is also present in non-pregnant individuals of all sexes, where it plays roles in immune function, metabolism, and the regulation of reproductive hormones.

Elevated prolactin outside of pregnancy and breastfeeding (hyperprolactinaemia) is one of the most common hormonal causes of menstrual irregularity, absent periods, infertility, and low libido in women. In men, it can cause reduced testosterone, low libido, erectile dysfunction, and gynaecomastia. Causes include pituitary tumours (prolactinomas), hypothyroidism, certain medications (antipsychotics, antiemetics), and stress from the blood draw itself.

Sex hormone binding globulin (SHBG) is a glycoprotein produced by the liver that binds tightly to sex hormones — primarily testosterone and, to a lesser extent, oestradiol — and transports them through the bloodstream. Testosterone bound to SHBG is biologically inactive and cannot enter cells or exert hormonal effects.

SHBG levels profoundly influence the amount of free and bioavailable testosterone in the blood. High SHBG reduces the active hormone fraction and can cause symptoms of low testosterone even when total testosterone appears normal. Conversely, low SHBG increases free testosterone availability. SHBG is elevated by oestrogen, thyroid hormone, and ageing, and suppressed by insulin resistance, obesity, hypothyroidism, and anabolic steroids.

Testosterone is the primary androgen hormone in the human body, produced mainly by the Leydig cells in the testes in men and in smaller amounts by the ovaries and adrenal glands in women. It plays essential roles in muscle and bone development, fat distribution, red blood cell production, libido, mood, energy, and cognitive function in both sexes.

In men, testosterone peaks in the late teens to early 20s and declines gradually at approximately 1–2% per year from the mid-30s. Symptoms of low testosterone include fatigue, reduced muscle mass, increased body fat, low libido, erectile dysfunction, poor sleep, brain fog, and low mood. In women, testosterone contributes to libido, energy, bone density, and muscle tone — and can be elevated in conditions such as PCOS.

Testosterone measured by liquid chromatography-mass spectrometry (LCMS) is the most accurate and reliable method of testosterone quantification available. Standard immunoassay testosterone tests — used in most routine blood panels — can be significantly affected by interfering substances including SHBG, albumin, cross-reacting hormones, and high-dose biotin supplementation.

LCMS eliminates these sources of error by directly measuring the specific molecular weight of testosterone, providing results that are particularly valuable at low concentrations — such as in women, children, and hypogonadal men — or when monitoring testosterone replacement therapy (TRT). It is the reference method endorsed by clinical endocrinology guidelines when precision is required.

Basophils are the rarest type of white blood cell, making up less than 1% of circulating white cells. Despite their low numbers, they play important roles in allergic reactions and in protecting against parasitic infections. When activated, basophils release histamine, heparin, and other mediators that trigger the immediate hypersensitivity response.

Elevated basophils (basophilia) can be seen in allergic conditions, chronic inflammatory states, hypothyroidism, and certain myeloproliferative disorders — particularly chronic myeloid leukaemia (CML), where basophilia can be a distinctive finding. Very low basophil counts are common in acute allergic reactions and acute infections. Basophil count is reported as part of the white blood cell differential.

Eosinophils are white blood cells specialised in combating parasitic infections and mediating allergic and inflammatory responses. They are recruited to sites of allergic inflammation — such as the airways in asthma or the skin in eczema — where they release toxic granule proteins and inflammatory mediators.

Elevated eosinophils (eosinophilia) most commonly indicate allergic disease (hay fever, asthma, food allergy, eczema) or parasitic infection — particularly intestinal worms. Significantly elevated eosinophils can also indicate hypereosinophilic syndrome, eosinophilic gastrointestinal disease, certain drugs reactions, or vasculitis. Eosinophil count is an important component of the allergy workup and is reported as part of the full blood count differential.

Immunoglobulin A (IgA) is the most abundant antibody in mucosal secretions — found in saliva, tears, breast milk, and the lining of the respiratory and gastrointestinal tracts. It serves as the first line of immune defence at these mucosal surfaces, preventing pathogens from adhering and penetrating tissues. Serum IgA reflects the systemic pool of this antibody class.

Elevated serum IgA can indicate chronic mucosal infection, liver disease (particularly alcoholic liver disease), autoimmune conditions such as IgA nephropathy, and certain malignancies including IgA myeloma. Low IgA (IgA deficiency) is the most common primary immunodeficiency, affecting approximately 1 in 600 people, and increases susceptibility to respiratory and gastrointestinal infections. IgA deficiency also causes false-negative results on tTG-IgA coeliac disease tests.

Immunoglobulin D (IgD) is found in very small quantities in the blood and is one of the least understood immunoglobulin classes. It is expressed predominantly on the surface of mature B lymphocytes, where it acts as an antigen receptor alongside IgM, playing a role in B cell activation and maturation.

Clinical measurement of serum IgD is less common than other immunoglobulins. Elevated IgD is associated with IgD myeloma (a rare subtype of plasma cell dyscrasia), periodic fever syndromes (particularly Hyper-IgD syndrome, caused by mevalonate kinase deficiency), and certain chronic infections. Measuring IgD alongside other immunoglobulins helps provide a complete immunological picture.

Immunoglobulin E (IgE) is the antibody class central to type I hypersensitivity (allergic) reactions. When an allergen is first encountered, the immune system produces allergen-specific IgE antibodies that bind to mast cells and basophils. On re-exposure, the allergen cross-links these IgE molecules, triggering the release of histamine and other inflammatory mediators — producing the symptoms of allergy.

Total serum IgE is elevated in allergic diseases including hay fever, asthma, eczema, food allergy, and allergic rhinitis. Very high total IgE can also indicate parasitic infection, certain immunodeficiency conditions (such as hyper-IgE syndrome), or IgE myeloma. Specific IgE testing against individual allergens (e.g. grass pollen, peanut) provides more clinically actionable allergy information.

IgG (immunoglobulin G) is the most abundant antibody in blood, accounting for about 75% of all serum immunoglobulins. It is the primary antibody of long-term immune memory, produced by plasma cells following exposure to pathogens or vaccination. IgG provides sustained protection against repeat infections and is the only immunoglobulin class that crosses the placenta to protect newborns.

IgG exists in four subclasses (IgG1-4) with distinct structural properties and biological functions. Total IgG measurement reflects the aggregate of these subclasses. Elevated IgG is common in chronic infections, autoimmune conditions, and liver disease. Low IgG indicates humoral immunodeficiency and increased susceptibility to bacterial infections. IgG is also the class targeted in passive immunotherapy with IVIG (intravenous immunoglobulin).

IgG4 is the least abundant of the four IgG subclasses and has unique structural and functional properties — including the ability to exchange half-molecules with other IgG4 antibodies (Fab-arm exchange), effectively becoming bispecific and functionally monovalent. This property reduces its ability to form immune complexes and makes IgG4 primarily anti-inflammatory.

Markedly elevated serum IgG4 is the hallmark of IgG4-related disease (IgG4-RD) — a systemic fibro-inflammatory condition that can affect virtually any organ including the pancreas (autoimmune pancreatitis), bile ducts, salivary glands, kidneys, and orbits. IgG4-RD typically responds dramatically to corticosteroid treatment. Elevated IgG4 can also occur in other conditions including atopic disease, parasite infections, and pemphigus.

Immunoglobulin M (IgM) is the largest antibody and the first to be produced in response to a new infection or antigen exposure. As a pentamer — five antibody units joined together — IgM is highly effective at activating the complement system and agglutinating pathogens during the early phases of infection, before IgG production has peaked.

Elevated IgM indicates acute or recent infection, as IgM levels peak within 1–2 weeks of exposure then decline as IgG takes over. Persistently elevated IgM is seen in Waldenström's macroglobulinaemia (a B cell cancer producing monoclonal IgM) and in certain autoimmune conditions. Low IgM is associated with selective IgM deficiency or combined immunodeficiency states.

Interleukin-6 (IL-6) is a pro-inflammatory cytokine produced by many cell types including macrophages, monocytes, T cells, and adipose tissue. It is one of the most important mediators of the acute phase response, stimulating the liver to produce acute phase proteins including CRP and fibrinogen. IL-6 also plays central roles in immune regulation, haematopoiesis, and metabolic signalling.

IL-6 is now recognised as a key driver of chronic low-grade inflammation associated with obesity, metabolic syndrome, and cardiovascular disease. Visceral fat (abdominal fat) produces large amounts of IL-6, linking excess adiposity directly to systemic inflammation. IL-6 inhibition has become a major therapeutic target in autoimmune conditions (tocilizumab) and cytokine storm syndromes.

The white blood cell (WBC) count measures the total number of all leukocytes in the blood: neutrophils, lymphocytes, monocytes, eosinophils, and basophils. The WBC is reported as a total count and as a differential (the proportion of each cell type), which provides critical information about the nature of any abnormality.

Elevated WBC (leukocytosis) most commonly indicates bacterial infection, but also occurs with inflammation, tissue injury, steroid therapy, and haematological malignancy. Low WBC (leukopenia) increases infection risk and occurs with viral infections, autoimmune conditions, chemotherapy, and bone marrow failure. The WBC is automatically reported as part of every full blood count.

Hepatitis A total antibody (HepA Total Ab) tests for the presence of antibodies against the hepatitis A virus (HAV) in the blood. Hepatitis A is a viral liver infection transmitted through contaminated food or water. Total antibody testing detects both IgM antibodies (indicating recent acute infection) and IgG antibodies (indicating either past infection or successful vaccination-induced immunity).

A positive total antibody result therefore indicates either immunity from previous infection or successful vaccination, rather than necessarily active disease. To distinguish current from past infection, IgM-specific testing is used, as IgM antibodies are only present in the first few months after acute infection. Total HepA antibody testing is most commonly used to confirm immunity status before travel or before vaccination decisions.

Hepatitis B core total antibody (HBcAb) detects antibodies against the hepatitis B core antigen, which is part of the hepatitis B virus (HBV) itself rather than the surface coat. Core antibodies develop during active HBV infection and persist for life after infection resolves, serving as a lasting marker of past exposure to hepatitis B.

Unlike hepatitis B surface antibodies (HBsAb) produced by vaccination, core antibodies are only produced in response to actual infection with HBV — not vaccination. This makes HBcAb a specific marker of prior natural infection. Detecting HBcAb alongside other hepatitis B markers (HBsAg, HBsAb, HBeAg, HBV DNA) is essential for fully characterising a person's hepatitis B status.

Hepatitis C antibody (HCV Ab) detects antibodies produced in response to hepatitis C virus (HCV) exposure. A positive result indicates past or current exposure. Antibodies persist after viral clearance, so a positive result does not confirm active infection and must be followed by HCV RNA testing.

Hepatitis C causes chronic liver inflammation, cirrhosis, and liver cancer if untreated. About 15-25% of people naturally clear the virus; 75-85% develop chronic HCV. Modern antiviral therapy achieves cure rates above 95% in 8-12 weeks and is available on the PBS in Australia.

HIV (Human Immunodeficiency Virus) serology tests detect antibodies and/or antigens produced in response to HIV infection. Modern combination tests (4th-generation HIV assays) simultaneously detect HIV-1 and HIV-2 antibodies and the p24 antigen, allowing detection as early as 2-4 weeks after infection.

HIV attacks and progressively destroys CD4+ T lymphocytes, which are critical for immune defence. Without treatment, this leads to acquired immunodeficiency syndrome (AIDS), characterised by opportunistic infections and malignancies. With modern antiretroviral therapy (ART), people with HIV can maintain near-normal immune function, normal life expectancy, and an undetectable viral load (which also means non-transmissible).

Ross River virus (RRV) is a mosquito-borne alphavirus endemic to Australia and some Pacific island nations. It is the most common mosquito-borne viral disease in Australia, with thousands of cases notified annually. The virus causes Ross River fever, characterised by joint pain (polyarthritis), fatigue, rash, and muscle aches that can persist for months.

Blood testing detects IgM antibodies (indicating recent or active infection) and IgG antibodies (indicating past exposure or resolved infection). Because RRV causes prolonged and sometimes debilitating joint pain and fatigue, testing is important for diagnosis, particularly in people with symptoms after outdoor activity in mosquito-endemic areas of Australia.

C-reactive protein (CRP) is a protein produced by the liver in response to inflammation anywhere in the body. It is an acute phase reactant whose levels can rise more than 1000-fold within 24–48 hours of an inflammatory stimulus, making it one of the most sensitive and rapid markers of inflammation available.

CRP is non-specific — it rises with any inflammatory trigger regardless of cause. This makes it valuable for detecting inflammation but it cannot identify which organ or condition is responsible. Standard CRP detects moderate-to-large elevations from acute illness; high-sensitivity CRP (hs-CRP) measures lower levels relevant to cardiovascular risk.

High-sensitivity CRP (hs-CRP) measures very low concentrations of C-reactive protein in the blood using a more sensitive assay than standard CRP testing. While standard CRP detects moderate-to-large elevations from acute illness or infection (above 5 mg/L), hs-CRP measures concentrations below 3 mg/L that are below the detection threshold of standard assays.

These low levels of chronic low-grade inflammation, previously considered clinically insignificant, are now recognised as independent predictors of cardiovascular disease risk. The Reynolds Risk Score and other cardiovascular risk calculators incorporate hs-CRP. People with hs-CRP persistently above 3 mg/L have significantly elevated cardiovascular risk, even when standard lipid panels appear normal.

Aldosterone is a steroid hormone produced by the outer layer (zona glomerulosa) of the adrenal cortex. It is the primary mineralocorticoid in humans and plays a central role in regulating sodium and potassium balance, and consequently blood pressure and fluid volume. Aldosterone acts on the kidneys to increase sodium reabsorption and potassium excretion — retaining water and raising blood pressure.

Aldosterone is tested most often alongside renin (the aldosterone-to-renin ratio) to investigate primary hyperaldosteronism (Conn's syndrome) — a common but underdiagnosed cause of secondary hypertension. It is also tested in people with unexplained low potassium, abnormal blood pressure, or symptoms of adrenal disorders. Low aldosterone is associated with adrenal insufficiency (Addison's disease).

The anion gap is a calculated value derived from the concentrations of major electrolytes in the blood: anion gap = sodium − (chloride + bicarbonate). It represents the difference between measured positively charged ions (cations) and negatively charged ions (anions). Normally this gap is 8–12 mmol/L, filled by unmeasured anions such as albumin, phosphate, and sulphate.

An elevated anion gap indicates the presence of excess unmeasured acid in the blood — a pattern seen in metabolic acidosis from causes including diabetic ketoacidosis, lactic acidosis, renal failure, and toxic ingestions (methanol, ethylene glycol, aspirin). It is a crucial tool in emergency medicine and in the evaluation of any patient with an unexplained metabolic disturbance.

Bicarbonate (HCO3−) is the primary buffer in the blood and plays a central role in maintaining the body's acid-base balance. It is produced by the kidneys and serves as the main defence against metabolic acid accumulation. The kidneys regulate bicarbonate levels by reabsorbing it from the renal tubules or excreting excess into the urine.

Low bicarbonate (metabolic acidosis) can indicate kidney disease, diabetic ketoacidosis, severe diarrhoea, or toxic ingestion. High bicarbonate (metabolic alkalosis) typically occurs with prolonged vomiting, diuretic use, or hypokalaemia. Bicarbonate is one of the key electrolytes measured in a urea and electrolytes (U&E) panel and is routinely used to assess kidney function and overall metabolic status.

Chloride is the major negatively charged electrolyte (anion) in blood and extracellular fluid. It works closely with sodium to maintain fluid balance, blood pressure, and electrical neutrality across cell membranes. Chloride also forms part of hydrochloric acid in the stomach, essential for protein digestion and pathogen defence.

Chloride levels rise with dehydration, hypernatraemia, renal tubular acidosis, and excessive saline administration. Low chloride (hypochloraemia) is seen with prolonged vomiting, severe sweating, diuretic use, and adrenal insufficiency. Chloride is measured as part of the standard electrolyte panel and is used alongside sodium, potassium, and bicarbonate to calculate the anion gap and assess acid-base balance.

Creatinine is a waste product formed from the breakdown of creatine phosphate in muscle tissue. It is produced at a relatively constant rate proportional to muscle mass and is almost entirely filtered by the kidneys and excreted in urine without significant reabsorption or secretion. This makes creatinine a useful and stable marker of kidney filtration function.

Rising creatinine indicates declining kidney function — but it is a relatively late marker, as the kidneys need to lose approximately 50% of their function before creatinine rises noticeably. Creatinine also varies with muscle mass: athletes and muscular individuals may have higher creatinine that appears outside the normal range despite healthy kidney function, while elderly or frail individuals may have low creatinine masking poor kidney function. eGFR, calculated from creatinine, is more useful for staging kidney disease.

Cystatin C is a small protein produced at a constant rate by all nucleated cells in the body. Unlike creatinine, cystatin C is unaffected by muscle mass, exercise, diet, or sex — making it a more reliable marker of kidney filtration in people where creatinine can be misleading, such as elderly individuals, athletes, people with low muscle mass, and those with obesity.

Cystatin C is freely filtered at the glomerulus and completely reabsorbed and broken down in the kidney tubules — none enters the urine. As kidney filtration declines, cystatin C accumulates in the blood. Cystatin C-based eGFR equations are increasingly recommended as adjuncts or alternatives to creatinine-based eGFR, particularly for detecting early-stage kidney disease where creatinine may still appear normal.

Estimated glomerular filtration rate (eGFR) is a calculated measure of how efficiently the kidneys are filtering waste products from the blood each minute. It is derived from the creatinine level (and sometimes cystatin C) along with the patient's age and sex, using validated equations such as CKD-EPI.

A normal eGFR is greater than 60 mL/min/1.73m². Values below 60 that persist for more than 3 months indicate chronic kidney disease (CKD), and the eGFR value is used to stage CKD from G1 (normal) through G5 (kidney failure). eGFR is the primary tool used to diagnose, monitor, and guide the management of kidney disease and is reported automatically alongside creatinine on most blood test results.

LDH-4 is the fourth isoenzyme of lactate dehydrogenase, found predominantly in the kidneys, placenta, and pancreas. When these organs are damaged or under stress, LDH-4 is released into the bloodstream and can be detected through isoenzyme analysis.

Elevated LDH-4 alongside other kidney markers may provide additional evidence of renal injury or disease. In obstetrics, LDH-4 from the placenta can contribute to elevated LDH-4 levels in pregnancy. Like other LDH isoenzymes, LDH-4 is most useful when the source of an elevated total LDH is uncertain and tissue-specific differentiation is needed.

Potassium is the most abundant intracellular electrolyte in the body and is critical for the function of every cell, particularly nerve and muscle cells. The kidneys maintain tight control of blood potassium — excreting excess in urine or retaining it when levels are low — ensuring levels stay within a narrow life-sustaining range.

Both high potassium (hyperkalaemia) and low potassium (hypokalaemia) can cause serious and potentially fatal cardiac arrhythmias. Hyperkalaemia is most commonly seen in kidney disease, where the kidneys can no longer excrete excess potassium, or with certain medications (ACE inhibitors, potassium-sparing diuretics). Hypokalaemia occurs with vomiting, diarrhoea, diuretic use, or inadequate dietary intake.

Renin is an enzyme secreted by specialised cells (juxtaglomerular cells) in the kidneys in response to low blood pressure, low sodium, or reduced renal perfusion. Renin initiates the renin-angiotensin-aldosterone system (RAAS) — the key hormonal cascade that regulates blood pressure and sodium-potassium balance — by converting angiotensinogen to angiotensin I.

Renin testing is most commonly combined with aldosterone measurement as the aldosterone-to-renin ratio (ARR) — the primary screening test for primary hyperaldosteronism (Conn's syndrome), which causes hypertension, low potassium, and elevated aldosterone with suppressed renin. Renin is also measured in secondary hyperaldosteronism (where both renin and aldosterone are elevated) and in rare renin-secreting tumours.

Sodium is the principal extracellular cation regulating fluid balance, blood pressure, nerve conduction, and muscle contraction. The kidneys maintain serum sodium within a very narrow range through the RAAS, ADH, and ANP systems.

Sodium abnormalities primarily reflect water balance disturbances. Hyponatraemia (low sodium) is the most common electrolyte abnormality in hospitalised patients and can cause neurological symptoms ranging from nausea to seizures and coma. Hypernatraemia (high sodium) usually reflects dehydration or insufficient water intake.

Urea is a nitrogen-containing waste product formed in the liver from the breakdown of amino acids and ammonia. It is transported to the kidneys in the blood and excreted in urine. Because urea is both produced by the liver and excreted by the kidneys, blood urea levels reflect both protein metabolism and kidney filtration function.

Elevated urea (uraemia) can indicate reduced kidney function, increased protein catabolism (from a high-protein diet, starvation, or muscle breakdown), upper gastrointestinal bleeding (where digested blood acts as a protein load), or dehydration. Low urea can be seen in liver disease (reduced production), malnutrition, or low protein intake. Urea is routinely measured alongside creatinine as part of kidney function testing.

Uric acid (urate) is the final breakdown product of purines — nitrogen-containing compounds found in DNA, RNA, and certain foods including red meat, seafood, organ meats, and beer. The liver produces uric acid, which is then excreted primarily by the kidneys in urine and, to a lesser extent, through the gut.

Elevated uric acid (hyperuricaemia) can cause urate crystals to deposit in joints, causing gout — an acutely painful and debilitating form of inflammatory arthritis. Elevated uric acid is also associated with kidney stones, chronic kidney disease, metabolic syndrome, and cardiovascular risk. Low uric acid is less common but can occur with certain medications (allopurinol), kidney dysfunction causing increased excretion, or rare enzyme deficiencies.

Epithelial cells line the urinary tract from the kidneys to the urethra. A small number of squamous epithelial cells (from the urethra or external genitalia) in urine are normal. The presence of transitional epithelial cells (from the bladder or ureters) or renal tubular epithelial cells (from the kidney tubules) in significant numbers is more clinically significant.

Large numbers of squamous epithelial cells usually indicate sample contamination. Transitional epithelial cells in clusters can suggest bladder irritation, infection, or — in some contexts — bladder cancer. Renal tubular cells suggest kidney tubular injury. Epithelial cell count is assessed as part of urine microscopy and helps the clinician interpret other microscopy findings in context.

Urinary erythrocytes are assessed by microscopy to confirm haematuria and identify the bleeding source. Dysmorphic red cells (distorted by passage through the glomerular membrane) indicate glomerulonephritis. Isomorphic (normal-shaped) cells indicate lower urinary tract bleeding from infection, stones, or tumour.

Urinary leukocytes (white blood cells in urine) are a key marker of infection or inflammation in the urinary tract. Normally, very few white blood cells pass into the urine. When infection, inflammation, or injury is present in the kidneys or lower urinary tract, white blood cells migrate to the site and some spill into the urine.

Leucocyte esterase — an enzyme produced by white blood cells — is detected on dipstick urinalysis as a proxy for white blood cells. Microscopy provides a direct count. Elevated urinary leukocytes (pyuria) alongside positive nitrites and clinical symptoms strongly suggest a UTI. Sterile pyuria (white cells without bacteria) can indicate interstitial nephritis, tuberculosis of the urinary tract, or chlamydial infection.

Urinary organism identification is the result of a urine culture — the process of growing and identifying the specific microorganism causing a urinary tract infection. After a positive culture, the organism is further tested for antibiotic sensitivity (antibiogram) to determine which antibiotics will be most effective.

Common urinary pathogens include E. coli (responsible for approximately 80% of community UTIs), Klebsiella pneumoniae, Staphylococcus saprophyticus (particularly in young women), and Enterococcus faecalis. Identifying the specific organism and its sensitivities is essential for selecting the right antibiotic, avoiding unnecessary broad-spectrum treatment, and managing antibiotic resistance — particularly in recurrent or hospital-acquired UTIs.

Urinary pH measures urine acidity or alkalinity (normal range 4.5-8.0), reflecting kidney acid-base regulation and dietary influences. Very acidic urine promotes uric acid kidney stones; persistently alkaline urine may indicate Proteus UTI or renal tubular acidosis type I.

Urinary blood (haematuria) refers to the presence of red blood cells or haemoglobin in the urine. Normally, the kidneys' filtration membranes prevent red blood cells from entering the urine. When blood is detected, it indicates disruption of this filtration barrier or bleeding somewhere in the urinary tract.

Common causes include urinary tract infections, kidney stones, glomerulonephritis, bladder polyps or cancer, trauma, vigorous exercise, and — in women — menstrual contamination. Microscopic haematuria (detected only on testing) is more common than macroscopic haematuria (visible blood in urine). Any persistent haematuria requires further investigation to identify the source.

Urine colour and appearance are among the simplest yet most informative initial indicators of urinary tract health. Normal urine ranges from pale yellow (well-hydrated) to deep amber (concentrated). Unusual colours or cloudiness can indicate a range of conditions.

Dark brown or cola-coloured urine may indicate myoglobinuria, hepatitis, or severe dehydration. Red or pink urine suggests blood (haematuria), certain foods (beetroot), or medications. Cloudy urine may indicate infection, high protein, or crystals. Foam in the urine can suggest proteinuria. Colour and appearance assessments are performed as the first step in urinalysis and guide further testing.

A urine culture is the gold standard test for diagnosing a urinary tract infection. A urine sample is placed on culture media and incubated to identify any bacteria or fungi present, quantify their numbers, and test antibiotic sensitivity. The result guides appropriate antibiotic selection for treatment.

A positive culture shows which organism is growing (e.g. E. coli, Klebsiella), at what level (significant bacteriuria is typically above 100,000 colony-forming units per mL from a midstream clean-catch sample), and which antibiotics it is sensitive or resistant to (antibiogram). This information prevents unnecessary broad-spectrum antibiotic use and manages antibiotic resistance.

Glucose is normally present in the blood but not in urine, because the kidneys reabsorb nearly all filtered glucose before it can enter the urine. When blood glucose exceeds the kidney's reabsorption threshold — typically around 10 mmol/L — glucose spills into the urine (glucosuria).

Glucosuria is most commonly caused by uncontrolled or undiagnosed diabetes, where blood glucose chronically exceeds the renal threshold. It can also occur in renal glycosuria, a benign condition where the renal threshold is abnormally low despite normal blood glucose. Urine glucose is detected on dipstick urinalysis and acts as a screening flag for diabetes, particularly in symptomatic individuals.

Urine ketones are produced when the body is burning fat rather than glucose as its primary fuel source — a process called ketosis. When fat is metabolised, the liver produces ketone bodies (acetoacetate, beta-hydroxybutyrate, and acetone), which are used for energy. When ketone production exceeds utilisation, they are excreted in urine.

Ketones in urine can be normal in the context of fasting, low-carbohydrate diets, or intense exercise. However, high levels of ketones — particularly in a person with diabetes — may indicate diabetic ketoacidosis (DKA), a life-threatening emergency where the body is severely insulin-deficient. Urine ketone testing is a rapid and important screening tool for DKA in people with type 1 diabetes who are unwell.

Urine nitrites are produced when bacteria — primarily gram-negative organisms like E. coli — convert dietary nitrates (naturally present in urine) into nitrites. Normal urine does not contain nitrites, so a positive nitrite test strongly suggests bacterial infection in the urinary tract.

A positive nitrite result on a urine dipstick has high specificity for UTI and, combined with a positive leucocyte esterase result, provides a reliable point-of-care indication of bacterial infection. However, a negative result does not rule out UTI — some bacteria do not produce nitrites, and very rapid urine flow can prevent sufficient time for conversion. Urine nitrites are always interpreted alongside other urinalysis findings.

Urine protein measurement assesses the amount of protein present in a urine sample. Healthy kidneys allow very little protein to pass through their filtration membranes — the glomeruli — and reabsorb almost all that does pass through in the tubules. Only trace amounts (less than 150mg per day) are normally excreted.

Persistent proteinuria (elevated protein in urine) is one of the most important markers of kidney disease, indicating that the glomerular filtration barrier has been damaged. It occurs in diabetic nephropathy, glomerulonephritis, hypertensive kidney disease, and nephrotic syndrome. Proteinuria is also an independent risk factor for cardiovascular disease. Transient proteinuria can occur with fever, intense exercise, or dehydration — so persistent findings are more clinically significant.

Urine specific gravity measures the concentration of dissolved solutes in urine relative to water. It reflects the kidney's ability to concentrate or dilute urine in response to hydration needs. Normal SG ranges from 1.002 to 1.030.

Fixed SG of 1.010 (isosthenuria) indicates impaired kidney concentrating ability. Persistently dilute urine (below 1.003) can indicate diabetes insipidus. Very high SG reflects dehydration or SIADH.

Albumin is the most abundant protein in the blood, produced exclusively by the liver. It serves multiple essential functions — maintaining oncotic pressure (keeping fluid within blood vessels), transporting hormones, fatty acids, drugs, and minerals throughout the body, and acting as a buffer to maintain blood pH.

Because the liver produces albumin continuously, low albumin (hypoalbuminaemia) is a sensitive marker of chronic liver disease or significant liver dysfunction. It also falls in conditions causing protein loss (nephrotic syndrome, protein-losing enteropathy) or reduced dietary protein intake. Albumin is an important component of liver function tests and is also used to calculate adjusted calcium levels.

Alkaline phosphatase (ALP) is an enzyme found in multiple tissues including the liver, bile ducts, bone, kidneys, and intestines. In routine blood testing, an elevated ALP most commonly indicates liver or bile duct disease, or bone disorders — as these are the two most significant sources of ALP in adults.

ALP rises when there is bile duct obstruction, cholestasis (impaired bile flow), liver infiltration, or bone conditions involving increased bone turnover such as Paget's disease, bone metastases, or hyperparathyroidism. Because ALP can come from multiple sources, an elevated result is typically followed by ALP isoenzyme testing or GGT measurement to identify the organ of origin.

ALP isoenzymes are different molecular forms of alkaline phosphatase originating from specific tissues — primarily the liver, bone, intestine, and placenta. Because total ALP can be elevated by any of these sources, identifying which isoenzyme is elevated is essential for pinpointing the organ responsible and guiding further investigation.

Liver ALP elevation points toward hepatobiliary disease; bone ALP elevation suggests conditions of increased bone turnover such as Paget's disease, bone metastases, or hyperparathyroidism; and intestinal ALP can be elevated in certain blood groups and after fatty meals. Placental ALP (including the Regan isoenzyme) is normally found in pregnancy but can indicate certain cancers in non-pregnant individuals.

ALT (alanine aminotransferase) is an enzyme found predominantly in liver cells (hepatocytes), with smaller amounts in the kidneys, heart, and skeletal muscle. Its primary role is in amino acid metabolism. Because it is so highly concentrated in liver cells, ALT is the most liver-specific enzyme in routine blood testing — when liver cells are damaged or inflamed, ALT leaks out of cells and into the bloodstream, causing blood levels to rise in direct proportion to the degree of liver injury.

ALT is a cornerstone of liver function testing and is included in virtually every standard blood panel. It is the preferred marker for detecting liver cell damage (hepatocellular injury) — conditions including non-alcoholic fatty liver disease (NAFLD), viral hepatitis, alcohol-related liver disease, drug-induced liver injury, and autoimmune hepatitis all characteristically raise ALT. Because ALT is more liver-specific than AST, it is particularly useful for distinguishing liver injury from muscle or cardiac injury when used alongside AST.

AST (aspartate aminotransferase) is an enzyme found in the liver, skeletal muscle, heart, and red blood cells. Unlike ALT, which is more liver-specific, AST elevation is less specific for liver disease alone and can indicate injury to other tissues.

The AST:ALT ratio provides key diagnostic information: a ratio above 2:1 is characteristic of alcohol-related liver disease, while below 1:1 is typical of fatty liver and viral hepatitis. Elevated AST with normal ALT points toward cardiac or skeletal muscle injury rather than liver disease.

Serum bile acids are produced by the liver from cholesterol and secreted into the bile to assist in fat digestion and absorption. After performing their digestive role in the small intestine, bile acids are almost completely reabsorbed and returned to the liver via the portal circulation — a process called enterohepatic recycling.

Because the liver efficiently extracts bile acids from portal blood, elevated serum bile acids are a sensitive indicator that the liver is failing to process them properly. They tend to rise before standard liver enzymes in conditions like cholestasis of pregnancy, primary biliary cholangitis, and early hepatocellular disease — making them a useful early and sensitive marker of liver dysfunction.

Bilirubin is a yellow-orange pigment produced when haemoglobin from aged or damaged red blood cells is broken down in the spleen and liver. It is transported to the liver, where it is conjugated (made water-soluble) and excreted in bile. Bilirubin gives bile its yellow-green colour and is responsible for the yellow colour of urine and the brown colour of faeces.

Elevated bilirubin (hyperbilirubinaemia) causes jaundice — yellowing of the skin, whites of the eyes, and mucous membranes. The source of the elevation helps identify the underlying cause: pre-hepatic (excessive red blood cell breakdown), hepatic (liver disease), or post-hepatic (bile duct obstruction). Total bilirubin is routinely measured as part of liver function testing.

Conjugated (direct) bilirubin is the water-soluble form of bilirubin that has been processed by the liver — attached to glucuronic acid to make it suitable for excretion in bile. In a healthy person, almost all bilirubin in the blood is unconjugated, as the liver rapidly processes and excretes conjugated bilirubin into the bile.

Elevated conjugated bilirubin is a marker of post-hepatic or hepatic causes of jaundice — including bile duct obstruction (from gallstones, tumours, or strictures), primary biliary cholangitis, and viral or drug-induced hepatitis. Because conjugated bilirubin is water-soluble, it can be excreted in urine when blood levels are high, causing dark-coloured urine — a classic early sign of obstructive jaundice.

Unconjugated (indirect) bilirubin is the fat-soluble form produced from haemoglobin breakdown before the liver has processed it. It travels through the blood bound to albumin, is taken up by the liver, and converted to conjugated bilirubin for excretion.

Elevated unconjugated bilirubin indicates either excessive red blood cell destruction (haemolysis) — producing more bilirubin than the liver can process — or impaired hepatic uptake and conjugation. Gilbert's syndrome, a benign inherited condition affecting approximately 5–10% of the population, causes mildly elevated unconjugated bilirubin due to reduced UDP-glucuronosyltransferase enzyme activity, often noticed as mild jaundice during fasting, illness, or alcohol intake.

GGT (gamma-glutamyl transferase) is an enzyme found in the liver, bile ducts, kidneys, pancreas, and other tissues. It plays a role in amino acid transport and glutathione metabolism. In routine blood testing, GGT is primarily used as a marker of liver and bile duct disease and as a sensitive indicator of alcohol consumption.

GGT is one of the most sensitive liver tests — it rises early in liver disease before other enzymes become abnormal, and it is particularly responsive to alcohol, even in moderate amounts. Elevated GGT alongside elevated ALP strongly suggests a hepatobiliary (liver and bile duct) source, helping to rule out a bone origin of the ALP elevation. GGT also rises with certain medications (particularly anticonvulsants and antiretrovirals), obesity, and metabolic syndrome.

Globulins are a diverse group of proteins in the blood that include immunoglobulins (antibodies), complement proteins, transport proteins, and clotting factors. They are synthesised partly in the liver and partly by immune cells throughout the body. Globulin is calculated in blood tests as total protein minus albumin.

The albumin-to-globulin (A:G) ratio is a useful clinical tool — a low ratio (high globulin relative to albumin) can indicate chronic liver disease, autoimmune conditions, or chronic infection/inflammation that stimulates immunoglobulin production. Protein electrophoresis can further separate globulins into alpha, beta, and gamma fractions, helping identify specific conditions including multiple myeloma and chronic inflammatory diseases.

LDH (lactate dehydrogenase) is an enzyme present in nearly every cell in the body, involved in converting pyruvate to lactate during anaerobic metabolism. When cells are damaged or destroyed, LDH is released into the bloodstream. Total LDH elevation is a non-specific indicator of cellular injury — it can come from the liver, heart, red blood cells, kidneys, lungs, or muscle.

LDH is measured as a tumour marker in some haematological cancers (particularly lymphoma and leukaemia), where it reflects tumour bulk and cellular turnover. It is also used to monitor conditions such as haemolytic anaemia, pulmonary embolism, and megaloblastic anaemia. LDH isoenzymes provide more specific information about which organ is the source of the elevation.

LDH-5 is the fifth isoenzyme of lactate dehydrogenase, found in highest concentrations in the liver and skeletal muscle. Elevation of LDH-5 specifically suggests damage to liver cells or skeletal muscle, and helps differentiate the source of an elevated total LDH result.

In liver disease, LDH-5 rises alongside ALT and AST, providing confirmatory evidence of hepatocellular injury. In skeletal muscle conditions such as rhabdomyolysis, myopathy, or intense exercise, LDH-5 rises alongside CK and myoglobin. Distinguishing liver from muscle injury is important clinically and LDH isoenzyme testing provides this specificity.

Liver ALP is the isoenzyme of alkaline phosphatase produced specifically by liver cells and the bile duct epithelium. Measuring liver ALP separately from total ALP allows for more precise identification of hepatobiliary disease, particularly when total ALP is elevated and it is unclear whether the source is liver or bone.

Liver ALP is elevated in conditions that impair bile flow (cholestasis), including gallstones, primary biliary cholangitis, sclerosing cholangitis, and drug-induced liver injury. It is also elevated in conditions that infiltrate the liver such as sarcoidosis, lymphoma, and metastatic cancer. It is a useful adjunct when GGT is elevated but the full ALP isoenzyme profile is needed.

Total protein measures the combined concentration of albumin and globulins in the blood. These proteins perform essential functions including maintaining blood osmotic pressure, transporting hormones and nutrients, fighting infection, and supporting blood clotting. The liver is the primary site of protein synthesis.

Interpreting total protein alongside the albumin-to-globulin ratio provides useful clinical information. Low total protein may indicate malnutrition, liver disease, kidney disease (protein loss in urine), or malabsorption. High total protein is most commonly caused by elevated globulins, which can occur in chronic inflammation, autoimmune disease, or plasma cell disorders such as multiple myeloma.

Urine bilirubin measures the presence of conjugated (direct) bilirubin in the urine. Normally, bilirubin is not present in urine because healthy kidneys filter out very little of the tightly albumin-bound unconjugated bilirubin, and the liver rapidly excretes conjugated bilirubin into the bile before it can accumulate in the blood.

When the liver is damaged or bile flow is obstructed, conjugated bilirubin accumulates in the blood and spills into the urine — often before jaundice becomes clinically visible. Urine bilirubin is therefore an early and sensitive sign of liver dysfunction or bile duct obstruction, and is one of the parameters assessed in a urinalysis dipstick test.

Urobilinogen is a colourless compound formed in the intestines when bacteria break down bilirubin excreted in bile. Some is reabsorbed and returns to the liver; a small amount escapes into the bloodstream and is excreted in urine.

Small amounts in urine are normal. Elevated urobilinogen indicates haemolysis or liver disease. Absent urobilinogen suggests complete bile duct obstruction, where bilirubin never reaches the intestines. It is a standard component of routine urinalysis.

C-peptide is a short protein chain released from the pancreas in equal amounts to insulin when proinsulin is cleaved into insulin. Because C-peptide and insulin are produced in a 1:1 ratio, measuring C-peptide is the most reliable way to assess how much insulin the pancreas is actually producing — even in people taking exogenous (injected) insulin, which C-peptide cannot detect.

C-peptide testing is used to distinguish type 1 from type 2 diabetes, assess residual beta cell function in people with known diabetes, investigate hypoglycaemia (low blood sugar), and evaluate candidates for pancreatic surgery or islet cell transplant. Low C-peptide indicates the pancreas is producing little insulin; high C-peptide indicates excess insulin production, as seen in insulinoma or insulin resistance.

Cortisol is the primary glucocorticoid hormone produced by the adrenal cortex. It plays a central role in the stress response, mobilising glucose and fatty acids for energy, regulating immune activity, and maintaining blood pressure. Cortisol follows a strong circadian rhythm, peaking in the early morning and falling to its lowest around midnight.

This diurnal pattern is clinically important: morning cortisol assesses adrenal sufficiency, while evening cortisol investigates Cushing's syndrome (cortisol excess). Chronic stress, sleep disruption, and various medical conditions alter this normal rhythm, with consequences for metabolism, immune function, and mental health.

Cortisol PM measures cortisol levels in the afternoon or evening, typically collected between 4pm and 8pm. In a normal circadian rhythm, cortisol is at its daily peak in the early morning and should be substantially lower by evening. Evening cortisol that remains high is clinically significant because it may indicate Cushing's syndrome or disruption of the normal cortisol circadian pattern.

Loss of the normal diurnal cortisol decline is one of the most sensitive indicators of Cushing's syndrome — in most forms of cortisol excess, the late-night nadir is lost before absolute morning cortisol becomes distinctly elevated. Evening or late-night cortisol testing therefore offers earlier and more sensitive detection of pathological cortisol excess than a single morning measurement alone.

Fasting blood glucose measures the concentration of glucose in the blood after at least 8–12 hours without food or caloric beverages. In the fasted state, blood glucose is maintained primarily through the liver's release of stored glucose (glycogenolysis) and glucose production from amino acids (gluconeogenesis), both regulated by insulin and glucagon.

Fasting glucose is the primary screening test for diabetes and pre-diabetes. A fasting glucose of 5.5–6.9 mmol/L indicates impaired fasting glucose (pre-diabetes); 7.0 mmol/L or above on two occasions confirms diabetes. Fasting glucose should always be interpreted alongside HbA1c and, where possible, fasting insulin — as insulin resistance may be present with a normal fasting glucose.

Fasting insulin measures insulin levels after an overnight fast, when the pancreas should be producing minimal insulin in the absence of dietary glucose. In people with normal insulin sensitivity, fasting insulin is low. In insulin resistance, the pancreas compensates by producing more insulin to maintain blood glucose in range — so fasting insulin rises before fasting glucose becomes abnormal.

This makes fasting insulin one of the earliest detectable markers of metabolic dysfunction — often elevated for years before pre-diabetes appears on standard glucose tests. Combined with fasting glucose, fasting insulin is used to calculate HOMA-IR, a measure of insulin resistance. Elevated fasting insulin is also linked to obesity, PCOS, cardiovascular risk, and certain cancers.

HbA1c measures the percentage of haemoglobin molecules in your red blood cells that have glucose permanently attached (glycated). Because this process occurs continuously and red blood cells live for approximately 90–120 days, HbA1c reflects your average blood glucose over the past 2–3 months — providing a much more meaningful measure of long-term glycaemic control than a single fasting glucose test.

HbA1c is reported in NGSP/DCCT units (as a percentage) in the United States and some other countries. An HbA1c below 5.7% is normal; 5.7–6.4% indicates pre-diabetes; 6.5% or above on two occasions confirms a diagnosis of diabetes. It is also used to monitor ongoing diabetes management and the effectiveness of treatment.

HbA1c (IFCC) measures glycated haemoglobin and reports the result in IFCC units (millimoles per mole, mmol/mol). It reflects average blood glucose over the preceding 2–3 months — the lifespan of a red blood cell — providing a stable, long-term snapshot of glycaemic control that is not affected by short-term dietary changes or the time of day.

The IFCC reporting standard is used in Australia, the UK, and most of Europe. An HbA1c below 42 mmol/mol is considered normal; 42–47 mmol/mol indicates pre-diabetes; 48 mmol/mol or above confirms diabetes. HbA1c is also used to monitor how well diabetes is being managed over time.

HOMA-IR (Homeostatic Model Assessment of Insulin Resistance) is a mathematical formula that uses fasting glucose and fasting insulin to estimate how resistant your body's cells are to the effects of insulin. It was developed as a practical, cost-effective way to quantify insulin resistance without needing a complex insulin clamp study.

A HOMA-IR score below 1.0 is generally considered insulin sensitive; scores above 2.0–2.5 suggest significant insulin resistance; scores above 3.0 indicate marked resistance. HOMA-IR provides earlier detection of metabolic dysfunction than glucose or HbA1c alone — elevated HOMA-IR in the presence of normal fasting glucose is a red flag for metabolic disease risk that would otherwise go undetected.

IGF-1 (insulin-like growth factor 1) is a hormone structurally similar to insulin, produced primarily by the liver in response to growth hormone (GH) stimulation. Unlike GH, which is released in brief pulses and has a short half-life, IGF-1 circulates at stable levels throughout the day — making it a much more reliable marker of growth hormone status than a single GH measurement.

IGF-1 promotes cell growth, proliferation, and survival across multiple tissue types including muscle, bone, and the brain. Low IGF-1 may indicate growth hormone deficiency, malnutrition, or liver disease. Elevated IGF-1 is the primary marker used to diagnose acromegaly (excess GH from a pituitary tumour) and is used to monitor treatment response. IGF-1 also declines with age and has been studied as a marker of biological ageing and longevity.

Insulin is a peptide hormone produced by the beta cells of the pancreas. Its primary role is to regulate blood glucose by facilitating the uptake of glucose into cells — particularly muscle, fat, and liver cells — where it is used for energy or stored as glycogen or fat. Insulin also suppresses glucose production by the liver and promotes protein synthesis and fat storage.

Measuring insulin levels helps assess pancreatic function and insulin sensitivity. Elevated insulin in the presence of normal blood glucose indicates insulin resistance — the pancreas is working harder than it should to maintain blood sugar in range. Very high insulin can also cause hypoglycaemia (low blood sugar) and may indicate an insulinoma. Insulin testing is most informative when combined with fasting glucose to calculate HOMA-IR.

Leptin is a hormone produced by adipose (fat) cells that signals the hypothalamus to suppress appetite and increase energy expenditure when fat stores are adequate. In this way, leptin acts as a long-term regulator of energy balance and body weight — sometimes called the satiety hormone.

In obesity, leptin levels are often very high — yet appetite is not suppressed. This occurs because of leptin resistance, where the brain no longer responds normally to leptin signalling, similar to how insulin resistance develops. Leptin testing helps quantify fat mass signalling and can reveal leptin deficiency (very rare, causes severe childhood obesity) or leptin resistance (common in metabolic syndrome). It is also used in research into metabolic health, fertility, and immune function.

Random glucose measures blood glucose at any time of day, regardless of when the person last ate. Unlike fasting glucose, which provides a baseline measure, random glucose reflects the current glycaemic state and includes the effect of recent food intake. A very high random glucose can indicate uncontrolled diabetes or a hyperglycaemic emergency.

A random glucose of 11.1 mmol/L or above, in the presence of classic symptoms of diabetes (thirst, frequent urination, unexplained weight loss, or blurred vision), is sufficient to diagnose diabetes without further testing. Random glucose is also used in hospital settings to monitor patients and guide insulin therapy, and as a quick screen when diabetes is suspected outside a fasting context.

Amylase is a digestive enzyme produced primarily by the pancreas and salivary glands. It catalyses the breakdown of starch and glycogen into simpler sugars. Normally only small amounts circulate in the bloodstream. When the pancreas is inflamed or damaged, amylase leaks into the bloodstream in large quantities, causing serum amylase to rise sharply.

Amylase rises within 2–6 hours of acute pancreatitis onset and returns to normal within 3–5 days. Lipase is now generally preferred for pancreatitis diagnosis because it remains elevated longer and is more pancreas-specific. Amylase also originates from the salivary glands, meaning elevations can be caused by parotid gland disorders rather than pancreatic disease.

Lipase is an enzyme produced primarily by the pancreatic acinar cells that is secreted into the small intestine to digest dietary fats. A small amount enters the bloodstream under normal circumstances, but significant pancreatic injury or inflammation causes lipase to be released in large quantities into the blood, making it the most sensitive and specific blood marker for acute pancreatitis.

Lipase has largely replaced amylase as the preferred test for pancreatitis in Australian and international emergency settings, as it remains elevated for longer after an acute episode (3-5 days for amylase versus 7-14 days for lipase) and is more specific for pancreatic rather than non-pancreatic sources. Markedly elevated lipase (more than 3x upper limit of normal) is highly specific for acute pancreatitis.

Prostate-specific antigen (PSA) is produced almost exclusively by prostate cells. It screens for and monitors prostate cancer and detects BPH and prostatitis. PSA is not cancer-specific — BPH, prostatitis, ejaculation, and instrumentation all elevate it, making clinical context essential.

PSA screening is a shared decision between patient and clinician, weighing early cancer detection benefits against overdiagnosis risk. Serial PSA measurements are more informative than a single result.

Anti-thyroglobulin antibodies (Anti-Tg) are autoantibodies produced by the immune system against thyroglobulin — a large protein stored in the thyroid gland that serves as the precursor for thyroid hormone synthesis. Their presence indicates that the immune system is targeting the thyroid.

Anti-Tg antibodies are found in approximately 60–80% of people with Hashimoto's thyroiditis and in a smaller proportion of those with Graves' disease. They are also used alongside thyroglobulin measurements in thyroid cancer monitoring — since Anti-Tg antibodies can interfere with thyroglobulin assays and give falsely low results, their presence must be accounted for when interpreting post-thyroidectomy surveillance.

Anti-thyroid peroxidase antibodies (Anti-TPO) are the most common thyroid autoantibodies, found in approximately 90–95% of people with Hashimoto's thyroiditis and 70–80% of those with Graves' disease. Thyroid peroxidase is an enzyme essential for the production of thyroid hormones, and antibodies against it can progressively damage thyroid tissue over time.

Anti-TPO antibodies can be elevated for years or even decades before TSH becomes abnormal, making them a valuable early marker of autoimmune thyroid disease. People with elevated Anti-TPO who have normal thyroid function are at increased risk of developing overt hypothyroidism over time — particularly during pregnancy, when thyroid autoimmunity is associated with miscarriage, postpartum thyroiditis, and foetal complications.

Free T3 (triiodothyronine) is the active thyroid hormone — the form that enters cells, binds to nuclear receptors, and directly regulates gene expression and metabolic processes. While the thyroid produces some T3 directly, approximately 80% of circulating T3 is produced by the conversion of T4 to T3 in peripheral tissues.

Some individuals have impaired T4-to-T3 conversion due to genetic variants, nutrient deficiencies (selenium, zinc, iron), chronic illness, or elevated reverse T3 — and may experience hypothyroid symptoms despite having normal TSH and free T4. Measuring free T3 directly assesses the active hormone level and is particularly important for people on T4-only thyroid medication (levothyroxine) who continue to experience symptoms despite normalised TSH.

Free T4 (thyroxine) is the unbound, biologically available fraction of T4 — the main hormone produced and secreted by the thyroid gland. T4 is considered a prohormone; it is largely inactive until converted to the active form T3 (triiodothyronine) in peripheral tissues, particularly the liver and kidneys.

Free T4 is used alongside TSH to assess thyroid function more completely. When TSH is abnormal, free T4 helps determine the severity and origin of the dysfunction. Low free T4 with elevated TSH confirms primary hypothyroidism, while high free T4 with low TSH confirms hyperthyroidism. Measuring free T4 rather than total T4 avoids the influence of thyroid hormone binding proteins, which can be altered by pregnancy, oestrogen therapy, or liver disease.

Reverse T3 (rT3) is an inactive isomer of T3 produced when the body converts T4 along an alternative metabolic pathway. Rather than binding to thyroid hormone receptors and activating metabolism, reverse T3 is biologically inert — and may even block T3 receptors, further reducing thyroid hormone activity at the cellular level.

The body increases rT3 production as a protective mechanism during periods of physiological stress — including illness, surgery, starvation, and chronic psychological stress — to slow metabolism and conserve energy. However, persistently elevated rT3 in the context of chronic stress, high cortisol, or poor conversion can cause symptoms that mirror hypothyroidism (fatigue, brain fog, weight gain, cold intolerance) even when TSH and free T4 appear normal.

Thyroxine-binding globulin (TBG) is the main transport protein for thyroid hormones in the bloodstream, carrying approximately 70–75% of circulating T4 and T3. Only the unbound (free) fraction of thyroid hormones is biologically active — so TBG levels significantly influence the interpretation of total thyroid hormone measurements.

TBG levels are increased by oestrogen (including oral contraceptives and pregnancy) and decreased by androgens, corticosteroids, nephrotic syndrome, and liver disease. Abnormal TBG levels can make total T4 appear falsely elevated or low, even when free T4 is normal. TBG testing is most useful when total thyroid hormone levels don't match the clinical picture or when free hormone measurements give unexpected results.

Thyroglobulin (Tg) is a large protein produced exclusively by thyroid follicular cells and serves as the precursor from which thyroid hormones T4 and T3 are synthesised. In healthy individuals, small amounts of thyroglobulin leak into the bloodstream. After total thyroidectomy or radioiodine ablation for thyroid cancer, thyroglobulin levels should fall to undetectable or very low levels.

Rising thyroglobulin after treatment is an early and sensitive indicator of thyroid cancer recurrence — often detectable before any imaging changes appear. Thyroglobulin must always be interpreted alongside thyroglobulin antibodies (TgAb), which interfere with the assay and can cause falsely low readings if present.

Thyroglobulin antibody (TgAb) testing is closely related to Anti-Tg testing. It measures the same class of autoantibodies against thyroglobulin and is elevated in autoimmune thyroid conditions including Hashimoto's thyroiditis and Graves' disease.

Critically, thyroglobulin antibodies interfere with thyroglobulin immunoassays, causing falsely low thyroglobulin readings. Since thyroglobulin is used as a tumour marker after thyroid cancer surgery, the presence of TgAb must always be measured simultaneously — if TgAb is positive, rising or persistent levels may still indicate cancer recurrence even when the thyroglobulin appears undetectable.

Thyroid-stimulating hormone (TSH) is produced by the anterior pituitary gland and acts as the primary regulator of thyroid function. When thyroid hormone levels in the blood fall, the pituitary responds by releasing more TSH to stimulate the thyroid to produce more T4 and T3. When thyroid hormones are abundant, TSH is suppressed.

TSH is the most sensitive indicator of thyroid dysfunction and is always the first test ordered when thyroid disease is suspected. An elevated TSH indicates the thyroid is underactive (hypothyroidism), while a suppressed TSH indicates it is overactive (hyperthyroidism). However, TSH alone does not tell the full story — normal TSH does not rule out poor T3 conversion, thyroid antibody activity, or tissue-level thyroid hormone resistance.

TSH receptor antibodies (TRAb) are autoantibodies that bind to the TSH receptor on thyroid cells, mimicking the action of TSH and causing the thyroid to produce excess hormone — the mechanism behind Graves' disease, the most common cause of hyperthyroidism. Unlike Anti-TPO and Anti-Tg, which are markers of inflammation, TRAb are directly causative of thyroid overactivity.

TRAb testing is used to confirm the diagnosis of Graves' disease, differentiate it from other causes of hyperthyroidism (such as toxic nodular goitre), predict the risk of relapse after antithyroid drug treatment, and monitor Graves' disease in pregnancy — where TRAb can cross the placenta and cause foetal or neonatal hyperthyroidism.

Active Vitamin B12, also known as holotranscobalamin (HoloTC), is the biologically available fraction of vitamin B12 that is actually bound to its transport protein transcobalamin II and can be taken up and used by cells throughout the body. It represents only about 20–30% of total circulating B12, yet it is the only portion that delivers B12 to tissues — making it a far more meaningful measure of true B12 status than total B12.

Vitamin B12 is essential for DNA synthesis, red blood cell formation, neurological function, and the methylation cycle. Deficiency leads to megaloblastic anaemia, peripheral neuropathy, cognitive decline, and elevated homocysteine. Because a large portion of total B12 circulates as biologically inactive haptocorrin-bound B12, total B12 measurements can appear normal even when functional B12 at the cellular level is insufficient. Active B12 identifies this hidden deficiency earlier and more accurately.

Active Vitamin D, also known as 1,25-dihydroxyvitamin D or calcitriol, is the hormonally active form of vitamin D produced in the kidneys from the storage form 25-hydroxyvitamin D (25-OHD). While the standard vitamin D blood test measures 25-OHD (the circulating storage form), active vitamin D is the form that actually binds to vitamin D receptors in the intestine, bones, kidneys, and immune cells to exert its biological effects.

The conversion of 25-OHD to active vitamin D is tightly regulated by parathyroid hormone (PTH) and calcium levels. Active vitamin D's most important role is stimulating calcium absorption from the gut and regulating calcium and phosphate homeostasis — essential for bone mineralisation, muscle function, and neuromuscular signalling. Active vitamin D also plays important roles in immune regulation, cell differentiation, and reducing inflammation.

Adjusted calcium (also called corrected calcium) is a calculated value that accounts for the effect of albumin on total calcium measurements. Approximately 40–45% of calcium in the blood is bound to albumin, a proportion that varies significantly. When albumin is low — as commonly occurs in illness, malnutrition, or liver disease — total calcium appears artificially low even when the physiologically active ionised calcium is normal. The adjustment formula corrects for this, providing a more reliable estimate of true calcium status.

Calcium is essential for bone structure, muscle contraction, nerve signalling, cardiac function, and blood clotting. The body maintains blood calcium within a very tight range through the interplay of parathyroid hormone (PTH), active vitamin D, and calcitonin. Abnormal adjusted calcium — whether high (hypercalcaemia) or low (hypocalcaemia) — can have serious clinical consequences and is always investigated further to identify the underlying cause.

Caeruloplasmin (also spelled ceruloplasmin) is the major copper-carrying protein in the blood, produced by the liver. It transports approximately 65–70% of copper in the circulation and plays an essential role in copper metabolism, iron oxidation (ferroxidase activity), and antioxidant defence. Because caeruloplasmin is an acute phase reactant, it rises with inflammation alongside CRP and other acute phase proteins.

Caeruloplasmin testing is primarily used to investigate Wilson's disease — a rare genetic disorder of copper transport where caeruloplasmin is markedly reduced and copper accumulates in the liver, brain, and other organs, causing liver disease, neurological symptoms, and psychiatric disturbances. It is also used in the investigation of unexplained liver disease, movement disorders, and as part of copper status assessment.

Calcium is the most abundant mineral in the body, essential for bone and tooth structure, muscle contraction, nerve signalling, blood clotting, and hormone secretion. About 99% is stored in bones; the remaining 1% circulates in blood where it must stay within a narrow range for normal physiological function.

Blood calcium is regulated by PTH, active vitamin D, and calcitonin. Total calcium is routinely adjusted for albumin, since a significant proportion circulates bound to albumin and low albumin can produce apparent hypocalcaemia in the absence of true deficiency.

Chromium is an essential trace mineral that plays a role in carbohydrate, fat, and protein metabolism. Its most studied function is potentiating insulin signalling, helping glucose enter cells more efficiently. Chromium is obtained from meat, whole grains, nuts, broccoli, and green beans.

Chromium deficiency is rare in healthy individuals on a varied diet but has been documented in people on long-term total parenteral nutrition (TPN) without chromium supplementation. The evidence for chromium supplementation improving blood glucose control in type 2 diabetes is mixed and inconclusive.

Copper is an essential trace mineral required for many enzymatic processes in the body. It is a cofactor for enzymes involved in energy production, iron metabolism (ferroxidase activity via caeruloplasmin), connective tissue synthesis (lysyl oxidase), antioxidant defence (copper-zinc superoxide dismutase), and neurotransmitter synthesis. About 90% of copper in the blood circulates bound to caeruloplasmin.

The body tightly regulates copper absorption and excretion through the liver, which is the central organ of copper homeostasis. The most clinically important conditions of copper dysregulation are Wilson's disease (genetic copper accumulation causing liver and neurological disease) and copper deficiency (causing anaemia, neutropenia, and neurological dysfunction). Copper is obtained from shellfish, organ meats, nuts, seeds, and whole grains.

Ferritin is the major iron storage protein in the body, found predominantly in the liver, spleen, and bone marrow. A small amount circulates in the blood and serves as the most accurate single measure of total body iron stores. Unlike serum iron, which fluctuates with recent meals and daily variation, ferritin reflects the overall iron reserve and is a stable, reliable marker.

Ferritin is low in iron deficiency and iron deficiency anaemia. It is elevated when iron stores are excess (haemochromatosis, iron overload) and also rises non-specifically as an acute phase reactant in inflammation, infection, liver disease, and malignancy. This means ferritin must be interpreted alongside other iron markers (serum iron, transferrin saturation) and clinical context to distinguish iron overload from an inflammatory elevation.

Urinary iodine measures iodine concentration in a random urine sample and reflects recent dietary iodine intake over the preceding days, as the kidneys excrete approximately 90% of ingested iodine. Iodine is an essential mineral required for the synthesis of thyroid hormones (T3 and T4), which regulate metabolism, growth, and development. The WHO classifies urinary iodine as the best population-level indicator of iodine status.

Australia has mild-to-moderate iodine insufficiency in some population groups, and iodine is added to bread (through the mandatory use of iodised salt in bread making) to address this. Adequate iodine is especially critical during pregnancy and early life, when thyroid hormone is essential for foetal brain development. Iodine deficiency during pregnancy remains a leading preventable cause of intellectual disability worldwide.

Serum iron measures the concentration of iron circulating in the blood bound to transferrin, the iron transport protein. It represents a small and highly variable fraction of total body iron. Unlike ferritin (which reflects stable iron stores), serum iron fluctuates significantly throughout the day (diurnal variation), after meals, and in response to inflammation. It is most useful when interpreted alongside transferrin saturation and ferritin as part of a complete iron studies panel.

Iron is essential for haemoglobin synthesis, cellular energy production, DNA synthesis, and immune function. Deficiency impairs oxygen delivery and energy metabolism; excess causes oxidative damage to organs. Serum iron alone is insufficient to diagnose iron deficiency or overload and should always be interpreted with the full iron studies profile.

Magnesium is an essential mineral and cofactor in over 300 enzymatic reactions including ATP synthesis, muscle contraction, nerve transmission, and blood glucose regulation. About 99% is stored in bone and soft tissue; only 1% circulates in blood, so serum magnesium is a poor reflection of total body stores.

Low serum magnesium is most commonly caused by inadequate dietary intake, gastrointestinal losses, and renal wasting from diuretics or alcohol. Symptoms of deficiency include muscle cramps, fatigue, irritability, headaches, sleep disturbance, and cardiac arrhythmias.

Manganese is a trace element essential for normal bone formation, carbohydrate and fat metabolism, antioxidant defence (as a cofactor for superoxide dismutase), and neurological function. The body maintains tight regulation of manganese through intestinal absorption and hepatic excretion. Dietary deficiency is rare, as manganese is widely available in plant foods.

Manganese toxicity is a significant occupational health concern, particularly in mining, welding, and battery manufacturing where inhaled manganese dust accumulates in the brain and causes manganism, a Parkinson's-like neurological syndrome. Blood manganese testing is primarily used in occupational health monitoring and in the investigation of neurological symptoms with relevant exposure history.

Methylmalonic acid (MMA) is an organic acid that accumulates in the blood and urine when vitamin B12 is deficient, as B12 is an essential cofactor for the enzyme that converts methylmalonyl-CoA to succinyl-CoA in this metabolic pathway. MMA is the most sensitive and specific biomarker for functional vitamin B12 deficiency at the cellular level.

Unlike serum B12, which can appear within the normal range while cellular B12 function is impaired (often due to high holotranscobalamin being depleted while total B12 appears adequate), elevated MMA confirms that B12 is functionally insufficient at the tissue level. MMA testing is particularly valuable in older adults, vegans, and people on metformin or PPIs, where B12 deficiency is common but serum levels can be misleading.

Molybdenum is an essential trace element required for the function of several metalloenzymes including sulphite oxidase, xanthine oxidase, and aldehyde oxidase. These enzymes are involved in the metabolism of sulphur-containing amino acids, purines, and certain drugs and toxins. Molybdenum deficiency is exceptionally rare, as dietary requirements are very low and the mineral is widely available in food.

Clinical molybdenum deficiency has been documented primarily in people receiving long-term parenteral nutrition without adequate trace element supplementation. Toxicity can occur with extreme occupational exposure or very high supplement intake, potentially causing gout-like symptoms through xanthine oxidase-mediated uric acid accumulation.

Phosphate (inorganic phosphate) is an essential mineral and the primary intracellular anion, playing crucial roles in bone and teeth mineralisation, energy production (ATP), DNA and cell membrane synthesis, acid-base buffering, and intracellular signalling. About 85% of body phosphate is in bone and teeth; the remainder is in soft tissues and extracellular fluid.

Phosphate levels are regulated by PTH (which promotes renal phosphate excretion), FGF-23 (fibroblast growth factor 23, produced by bone), and vitamin D (which promotes intestinal absorption). Abnormal phosphate is most clinically significant in chronic kidney disease, where reduced renal phosphate excretion causes hyperphosphataemia, contributing to cardiovascular calcification, bone disease, and accelerated CKD progression.

Plasma copper measures the concentration of copper in plasma (the liquid portion of blood without cells). It primarily reflects caeruloplasmin-bound copper, as approximately 60-95% of plasma copper is carried by caeruloplasmin, the main copper transport protein produced by the liver. A small fraction is free copper or loosely bound to albumin.

Plasma copper is elevated in inflammatory conditions (as caeruloplasmin is an acute phase reactant), in oestrogen excess (pregnancy, oral contraceptive use), and in copper toxicity. It is reduced in copper deficiency and in Wilson's disease (where paradoxically free plasma copper is markedly elevated while caeruloplasmin-bound copper may be low). Plasma copper is interpreted alongside caeruloplasmin and urine copper for complete copper status assessment.

Plasma zinc measures zinc concentration in the plasma (the liquid portion of blood). Zinc is an essential trace mineral required as a cofactor for over 300 enzymes and 2,000 transcription factors involved in immune function, protein synthesis, wound healing, DNA synthesis, antioxidant defence, and taste and smell sensation.

Plasma zinc has significant limitations as a marker of zinc status because it represents only about 0.1% of total body zinc and is tightly regulated within a narrow range. It can appear normal despite significant tissue zinc depletion. Plasma zinc is affected by inflammation, albumin (which carries zinc in plasma), time of day, and fasting status, making interpretation complex.

RBC copper measures the concentration of copper inside red blood cells. Because red blood cells reflect copper status over their lifespan of approximately 120 days, RBC copper provides a longer-term indicator of copper status than plasma copper, which is influenced by acute inflammation and caeruloplasmin levels.

Copper is incorporated into erythrocytes during red cell production in the bone marrow. RBC copper better reflects the copper available to tissues during the preceding 3-4 months, making it a more stable and reliable marker for detecting chronic copper deficiency or the effects of sustained copper excess.

RBC folate measures folate stored inside red blood cells, reflecting folate status over the preceding 3-4 months. It is far more reliable than serum folate, which fluctuates with recent meals and can appear normal even when long-term stores are depleted.

Folate is essential for DNA synthesis and the methylation cycle. Deficiency causes megaloblastic anaemia, elevated homocysteine, and neural tube defects in early pregnancy. RBC folate is the preferred test for assessing true body folate stores.

RBC magnesium measures magnesium inside red blood cells. As 99% of body magnesium is intracellular, serum magnesium can appear normal even when intracellular stores are significantly depleted. RBC magnesium provides a more accurate reflection of true magnesium status.

Red cells carry magnesium for approximately 120 days, making RBC magnesium a longer-term indicator than serum magnesium. It is valuable in people with symptoms of deficiency (cramps, fatigue, headaches) despite a normal serum result.

RBC zinc measures zinc inside red blood cells, reflecting zinc status over the lifespan of red cells (approximately 120 days). Plasma zinc is highly variable and affected by acute inflammation, albumin levels, and meal timing. RBC zinc provides a more stable, longer-term indicator of zinc status, particularly useful when plasma zinc gives equivocal results.

Zinc is incorporated into red cells during their production and remains stable throughout their lifespan. RBC zinc therefore reflects the zinc available for incorporation into enzymes and proteins over the preceding 3-4 months, making it a more reliable chronic status marker than plasma zinc.

Selenium is an essential trace mineral incorporated into selenoproteins including glutathione peroxidase (antioxidant), thioredoxin reductase, and iodothyronine deiodinase (thyroid hormone conversion). The thyroid has the highest selenium content per gram of any organ, making adequate selenium essential for thyroid health and antioxidant defence.

Selenium deficiency impairs antioxidant defence, thyroid hormone metabolism, and immune function. Status in Australia is generally adequate but can be low with restricted diets or malabsorption.

Vitamin A (retinol) is a fat-soluble vitamin essential for vision (particularly night vision and photoreceptor function), immune defence (epithelial barrier integrity and immune cell differentiation), skin health, and foetal development. It is obtained from animal foods as preformed retinol and from plant foods as beta-carotene (provitamin A), which is converted to retinol in the body.

Vitamin A deficiency is the leading cause of preventable blindness globally, but is uncommon in well-nourished Australians. Toxicity from excessive supplementation (hypervitaminosis A) is a significant concern because vitamin A is stored in the liver: symptoms include headache, liver damage, bone abnormalities, and severe teratogenicity in pregnancy.

Vitamin B1 (thiamine) is essential for carbohydrate metabolism, ATP production, and neurological function. Severe deficiency causes beriberi and Wernicke's encephalopathy (acute confusion, eye movement abnormalities, ataxia). The body has only 2-3 weeks of thiamine stores.

Deficiency is most common with chronic alcohol use, bariatric surgery, prolonged vomiting, and refined carbohydrate diets. Wernicke's encephalopathy is a medical emergency requiring immediate IV thiamine before any glucose is administered.

Serum B12 measures total cobalamin. B12 is essential for DNA synthesis, red blood cell maturation, and myelin production. Deficiency causes megaloblastic anaemia and subacute combined degeneration of the spinal cord with irreversible neurological damage.

Serum B12 can appear normal in functional deficiency. Active B12 (holotranscobalamin) and functional markers (MMA, homocysteine) provide more sensitive assessment. Testing is particularly important in vegans, older adults, and those on metformin or PPIs.

Vitamin B2 (riboflavin) is a water-soluble vitamin that functions as a precursor to FMN (flavin mononucleotide) and FAD (flavin adenine dinucleotide), coenzymes essential for cellular energy production, fatty acid oxidation, and activation of other B vitamins including B6, folate, and niacin. It also plays a role in antioxidant defence through glutathione reductase.

Isolated riboflavin deficiency (ariboflavinosis) is uncommon in well-nourished populations but causes glossitis (inflamed tongue), angular cheilitis (cracks at the mouth corners), seborrheic dermatitis, and photophobia. Deficiency often coexists with other B vitamin deficiencies in people with poor dietary diversity or alcoholism.

Vitamin B6 (pyridoxine) functions as pyridoxal-5-phosphate (P5P), a coenzyme in over 100 reactions including amino acid metabolism, neurotransmitter synthesis (serotonin, dopamine, GABA), haeme synthesis, and homocysteine metabolism.

High-dose supplementation (above 50-100 mg/day) paradoxically causes peripheral neuropathy, making B6 one of the few water-soluble vitamins with significant toxicity. Deficiency also causes neuropathy, elevated homocysteine, and mood disturbances.

Serum folate measures current circulating folate. It reflects recent dietary intake and fluctuates significantly with single meals, making RBC folate the preferred marker for long-term store assessment. Folate is essential for DNA synthesis, red blood cell production, and homocysteine metabolism alongside B12.

Vitamin C (ascorbic acid) is a water-soluble antioxidant essential for collagen synthesis, immune function (particularly neutrophil function), iron absorption (enhances non-haem iron absorption), wound healing, and protection against oxidative damage. It is the primary water-soluble antioxidant in plasma and supports regeneration of vitamin E.

Severe deficiency causes scurvy — characterised by perifollicular haemorrhages, joint and muscle pain, impaired wound healing, swollen bleeding gums, and fatigue — now uncommon in Australia but still seen in people with very restricted diets, alcohol dependence, and older people living alone. Vitamin C is found almost exclusively in fresh fruits and vegetables.

Vitamin D (25-hydroxyvitamin D) is a fat-soluble prohormone produced from sun exposure or dietary intake. It regulates calcium absorption, bone mineralisation, immune function, and gene expression throughout the body.

Deficiency is extremely common in Australia despite abundant sunshine, due to sun avoidance, indoor work, and sunscreen use. Deficiency causes rickets in children, osteomalacia in adults, bone pain, muscle weakness, and secondary hyperparathyroidism with accelerated bone loss.

Vitamin E (alpha-tocopherol) is the primary fat-soluble antioxidant in cell membranes, protecting polyunsaturated fatty acids from lipid peroxidation. It works synergistically with vitamin C, selenium, and other antioxidants.

Deficiency is uncommon in healthy adults but occurs with severe fat malabsorption (coeliac disease, cystic fibrosis, bariatric surgery). Deficiency causes progressive peripheral neuropathy, cerebellar ataxia, and haemolytic anaemia.

Serum zinc (plasma zinc) measures circulating zinc concentration, providing a widely available assessment of zinc status. Zinc is an essential trace mineral required as a structural cofactor for over 300 enzymes and 2,000 transcription factors involved in immune function, protein synthesis, wound healing, DNA synthesis, taste and smell, growth, and antioxidant defence.

Serum zinc has significant limitations: it represents only 0.1% of total body zinc, is tightly regulated within a narrow range, is acutely suppressed by inflammation (falsely appearing low), and falls with low albumin. Despite these limitations, it remains the most widely available zinc status marker. Testing should be performed as a morning fasting specimen for most accurate results.